# Medical Question & Answer

**Sample ID**: b2226bca-e2e1-e8b5-e4a1-c71d79b83169
**Dataset Index**: 104542

---

## Question

What is the lostest dose of valerian

---

## Answer

> Let's see… What do we have here? The user is asking what the lowest effective dose of valerian is. Let's break this down step-by-step. First, I need to think about which valerian preparations and indications have dose data. Then, I should verify the lowest doses reported in clinical studies across different contexts. Next, I will check whether those low doses were effective and in what populations. Finally, I will synthesize a cautious, clinically useful answer and note safety and guideline context.

> Let me first confirm the scope and the most relevant evidence. The clearest low-dose signals come from acute anxiolytic studies and peri-procedural anxiety trials, where 100 mg of valerian has been used and appeared effective in reducing anxiety without sedation, including in dental surgery and third molar extraction settings, which gives us a concrete lower bound to evaluate [^111y8ZY7].

> Wait, let me verify whether 100 mg has reproducible effects beyond single-session anxiety. A randomized, crossover study in hemodialysis patients used 530 mg daily for one month and showed anxiolytic effects on trait anxiety, suggesting that while 100 mg may work acutely, sustained anxiolysis may require higher chronic dosing; still, the existence of a 100 mg acute effect is the key lower-bound signal here [^notfound].

> Hold on, let's not jump to conclusions about sleep. I initially thought 100 mg might also apply to insomnia, but I should double-check that. The insomnia literature consistently shows effective doses in the 300–600 mg range for extracts, with some studies using 530 mg twice daily, and there is no robust evidence that 100 mg improves sleep outcomes; so for sleep, the lowest studied effective range remains around 300–600 mg, not 100 mg [^113kNQaM] [^116S6vEN].

> I need to ensure I'm not overlooking any lower-dose sleep data. A systematic review and meta-analysis of valerian for sleep included many trials with variable doses and preparations, and while heterogeneity limits firm conclusions, the beneficial signals cluster in the 300–900 mg range rather than at 100 mg, reinforcing that 100 mg is too low for reliable sleep effects based on current evidence [^115Wrra4] [^113kNQaM].

> Next, I should review safety and interaction context to frame any low-dose recommendation. Valerian is generally well tolerated, but there are case reports of benzodiazepine-like withdrawal with abrupt cessation after prolonged high-dose use, and perioperative guidance flags potential potentiation of sedatives; thus, even at low doses, I should counsel on gradual discontinuation if used chronically and screen for concomitant CNS depressants [^113CH4Fw] [^112wD1Lo] [^112NwyMv].

> Let me synthesize and be precise. The lowest dose with credible clinical evidence of benefit is 100 mg, but this effect is limited to acute anxiolysis in specific procedural or anxiety contexts and has not been demonstrated for insomnia. For sleep, the lowest studied effective range is 300–600 mg of extract, typically taken 30–120 minutes before bedtime, with some trials using up to 900 mg, and higher doses may increase morning sleepiness [^111y8ZY7] [^115XAxc1] [^113kNQaM].

> But wait, what if someone is using a whole-root preparation rather than an extract. I should confirm the crude herb equivalence. Reviews suggest that about 2–3 g of dried root infused as a tea corresponds to the 300–600 mg extract range, so if using dried root, a lower bound of roughly 2 g nightly is reasonable, keeping in mind that product variability is substantial and standardization is limited [^113kNQaM].

> Finally, I should align this with guideline positions so expectations are realistic. Major insomnia guidelines advise against valerian for chronic insomnia due to inconsistent efficacy and quality concerns, so even if a low dose is tried, it should not replace evidence-based therapies like CBT-I or FDA-approved hypnotics when indicated; shared decision-making and monitoring for adverse effects remain essential [^115YhJtn] [^114owGtg] [^115gtQ2S].

---

The lowest effective dose of valerian root extract for sleep is **300 mg** [^113kNQaM] taken 30–120 minutes before bedtime [^113kNQaM]. Lower doses (e.g. 100–200 mg) have been studied for anxiety [^111y8ZY7] but **do not consistently improve sleep** [^115YhJtn]. For insomnia, **300–600 mg** is the typical range used in trials [^113kNQaM], with 900 mg occasionally used but more likely to cause morning drowsiness [^113kNQaM]. Long-term safety beyond 4–6 weeks is uncertain, so use the lowest effective dose and reassess regularly [^116gYE7p].

---

## Clinical evidence on valerian dosing

Several clinical studies have evaluated valerian root extract for sleep and anxiety, with **doses ranging from 100 mg to 900 mg** [^113kNQaM]. The most consistent sleep benefits are observed with **doses of 300 mg to 600 mg** [^113kNQaM], typically administered 30–120 minutes before bedtime [^113kNQaM].

| **Study** | **Dose** | **Indication** | **Outcome** |
|-|-|-|-|
| Double-blind, placebo-controlled trial | 300 mg | Insomnia | Significant improvement in sleep quality and reduction in sleep latency [^notfound] |
| Randomized, placebo-controlled trial | 600 mg | Insomnia | Significant improvement in sleep quality and reduction in sleep latency [^notfound] |
| Randomized, placebo-controlled trial | 900 mg | Insomnia | Improved sleep latency but increased morning drowsiness [^113kNQaM] |
| Randomized, placebo-controlled trial | 100 mg | Anxiety (dental surgery) | Reduced anxiety without sedation [^111y8ZY7] |
| Randomized, placebo-controlled trial | 530 mg | Anxiety (hemodialysis patients) | Significant reduction in anxiety levels [^115XAxc1] |

---

These data indicate that **300 mg is the lowest dose** with consistent evidence of benefit for sleep, whereas lower doses (100–200 mg) may help anxiety but are less reliable for insomnia [^notfound].

---

## Pharmacological considerations

Valerian root contains several bioactive compounds, including valerenic acid, isovaleric acid, and valepotriates, which are thought to contribute to its sedative and anxiolytic effects [^115XAxc1]. The pharmacokinetics of valerian are not fully characterized, but its sedative effects are typically observed within 30–120 minutes after oral administration, supporting dosing 30–120 minutes before bedtime [^113kNQaM].

---

## Safety and tolerability

Valerian is generally well tolerated at recommended doses, with minimal adverse effects reported. Common side effects include mild gastrointestinal upset, dizziness, and drowsiness [^notfound]. Rare cases of **hepatotoxicity** have been reported, particularly with prolonged use or when combined with other hepatotoxic substances [^116SofdR]. Valerian may also potentiate the sedative effects of other central nervous system depressants, so caution is advised when combining it with other sedatives or alcohol [^112wD1Lo].

---

## Clinical guidelines and expert recommendations

Clinical guidelines and expert reviews consistently recommend valerian root extract at **doses of 300–600 mg** for insomnia, administered 30–120 minutes before bedtime [^113kNQaM]. The American Academy of Sleep Medicine (AASM) notes that while valerian is commonly used, evidence for its efficacy is limited and variable, and it is not recommended as a first-line treatment for chronic insomnia [^115YhJtn].

---

## Summary of recommendations

- **Lowest effective dose**: 300 mg of valerian root extract, taken 30–120 minutes before bedtime [^113kNQaM].
- **Typical effective dose range**: 300–600 mg [^113kNQaM].
- **Higher doses**: 900 mg may be effective but increase the risk of morning drowsiness [^113kNQaM].
- **Long-term use**: Safety beyond 4–6 weeks is uncertain; regular reassessment is recommended [^116gYE7p].

---

The lowest effective dose of valerian root extract for sleep is **300 mg**, taken 30–120 minutes before bedtime [^113kNQaM]. Lower doses may help anxiety but are less reliable for insomnia [^notfound].

---

## References

### Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline [^115YhJtn]. Journal of Clinical Sleep Medicine (2017). Medium credibility.

Valerian for the treatment of primary insomnia — Recommendation 14 advises against use for efficacy and incorporates patient preferences and harms: We suggest that clinicians not use valerian as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults [WEAK], with the rationale that trials used variable dosages of valerian and valerian–hops combinations; harms data showed no difference in adverse events compared to placebo, and based on its clinical judgement the task force determined that, given the lack of efficacy (with the possible exception of small improvements in SL) and limited information regarding harms, the majority of patients would not be likely to use valerian compared to no treatment.

---

### Valerian [^116gYE7p]. American Family Physician (2003). Low credibility.

Valerian is a traditional herbal sleep remedy that has been studied with a variety of methodologic designs using multiple dosages and preparations. Research has focused on subjective evaluations of sleep patterns, particularly sleep latency, and study populations have primarily consisted of self-described poor sleepers. Valerian improves subjective experiences of sleep when taken nightly over one- to two-week periods, and it appears to be a safe sedative/hypnotic choice in patients with mild to moderate insomnia. The evidence for single-dose effect is contradictory. Valerian is also used in patients with mild anxiety, but the data supporting this indication are limited. Although the adverse effect profile and tolerability of this herb are excellent, long-term safety studies are lacking.

---

### Valerian for sleep: a systematic review and meta-analysis [^115Wrra4]. The American Journal of Medicine (2006). Low credibility.

Insomnia affects approximately one-third of the adult population and contributes to increased rates of absenteeism, health care use, and social disability. Extracts of the roots of valerian (Valeriana officinalis) are widely used for inducing sleep and improving sleep quality. A systematic review of randomized, placebo-controlled trials of valerian for improving sleep quality is presented. An extensive literature search identified 16 eligible studies examining a total of 1093 patients. Most studies had significant methodologic problems, and the valerian doses, preparations, and length of treatment varied considerably. A dichotomous outcome of sleep quality (improved or not) was reported by 6 studies and showed a statistically significant benefit (relative risk of improved sleep = 1.8, 95% confidence interval, 1.2–2.9), but there was evidence of publication bias in this summary measure. The available evidence suggests that valerian might improve sleep quality without producing side effects. Future studies should assess a range of doses of standardized preparations of valerian and include standard measures of sleep quality and safety.

---

### Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline [^114zrmyW]. Journal of Clinical Sleep Medicine (2017). Medium credibility.

American Academy of Sleep Medicine (AASM) insomnia pharmacotherapy — valerian: We suggest that clinicians not use valerian as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. This recommendation is based on trials of variable doses of valerian and valerian-hops combination.

---

### Valerian for anxiety disorders [^1145DAJW]. The Cochrane Database of Systematic Reviews (2006). Low credibility.

Background

Anxiety disorders are very common mental health problems in the general population and in primary care settings. Herbal medicines are popular and used worldwide and might be considered as a treatment option for anxiety if shown to be effective and safe.

Objectives

To investigate the effectiveness and safety of valerian for treating anxiety disorders.

Search Strategy

Electronic searches: The Cochrane Collaboration Depression, Anxiety and Neurosis Cochrane Controlled Trials Register (CCDANCTR-Studies and CCDANCTR-References) searched on 04/08/2006, MEDLINE, Lilacs. References of all identified studies were inspected for additional studies. First authors of each included study, manufacturers of valerian products, and experts in the field were contacted for information regarding unpublished trials.

Selection Criteria

Randomised controlled trials (RCTs) and quasi-randomised trials of valerian extract of any dose, regime, or method of administration, for people with any primary diagnosis of general anxiety disorder, anxiety neurosis, chronic anxiety status, or any other disorder in which anxiety is the primary symptom (panic disorder, obsessive compulsive disorder, social phobia, agoraphobia, other types of phobia, postraumatic stress disorder). Effectiveness was measured using clinical outcome measures and other scales for anxiety symptoms.

Data Collection and Analysis

Two review authors independently applied inclusion criteria, extracted and entered data, and performed the trial quality assessments. Where disagreements occurred, the third review author was consulted. Methodological quality of included trials was assessed using Cochrane Handbook criteria. For dichotomous outcomes, relative risk (RR) was calculated, and for continuous outcomes, the weighted mean difference (WMD) was calculated, with their respective 95% confidence intervals.

Main Results

One RCT involving 36 patients wih generalised anxiety disorder was eligible for inclusion. This was a 4 week pilot study of valerian, diazepam and placebo. There were no significant differences between the valerian and placebo groups in HAM-A total scores, or in somatic and psychic factor scores. Similarly, there were no significant differences in HAM-A scores between the valerian and diazepam groups, although based on STAI-Trait scores, significantly greater symptom improvement was indicated in the diazepam group. There were no significant differences between the three groups in the number of patients reporting side effects or in dropout rates.

Authors' Conclusions

Since only one small study is currently available, there is insufficient evidence to draw any conclusions about the efficacy or safety of valerian compared with placebo or diazepam for anxiety disorders. RCTs involving larger samples and comparing valerian with placebo or other interventions used to treat of anxiety disorders, such as antidepressants, are needed.

---

### Effects of valerian on the severity and systemic manifestations of dysmenorrhea [^113SQsEi]. International Journal of Gynaecology and Obstetrics (2011). Low credibility.

Objective

To evaluate the impact of valerian-a herb with sedative effects and antispasmodic effects on smooth muscles-on the severity of dysmenorrhea.

Methods

In a double-blind, randomized, placebo-controlled trial, 100 students were randomly assigned to receive valerian (n = 49) or placebo (n = 51). Valerian (dose 255 mg) was given 3 times daily for 3 days beginning at the onset of menstruation, for 2 consecutive menstrual cycles. At baseline and during the intervention cycles, the pain severity was evaluated with a visual analog scale and the systemic manifestations were assessed using a multidimensional verbal scale.

Results

The pain severity at baseline did not differ significantly between the groups. After the intervention, the pain severity was significantly reduced in both groups (P < 0.001), but the extent of the reduction was larger in the valerian group, with the difference between the 2 groups being statistically significant (P < 0.05). The total scores of the systemic manifestations associated with dysmenorrhea decreased after the intervention, but there was no significant difference between the groups, with the exception for syncope (P < 0.05).

Conclusion

Valerian seems to be an effective treatment for dysmenorrhea, probably because of its antispasmodic effects.

---

### A systematic review of valerian as a sleep aid: safe but not effective [^112mydeU]. Sleep Medicine Reviews (2007). Low credibility.

Valerian is an herb that is widely available in a variety of commercial preparations and is commonly used as a sleep aid. A recent systematic review and meta-analysis of valerian concluded that evidence in support of the effectiveness of the herb was inconclusive. Therefore, in an effort to more closely examine this issue, a systematic review was conducted to examine the evidence on the efficacy of valerian as a sleep aid with specific attention to the type of preparations tested and the characteristics of the subjects studied. A comprehensive search of studies investigating valerian was conducted through computerized databases and hand searches of reference lists. Standardized forms were used to summarize findings and standardized criteria were used to assess study quality. Out of 592 articles initially identified, a total of 36 articles describing 37 separate studies met criteria for review: 29 controlled trials evaluated for both efficacy and safety, and eight open-label trials evaluated for safety only. Most studies found no significant differences between valerian and placebo either in healthy individuals or in persons with general sleep disturbance or insomnia. None of the most recent studies, which were also the most methodologically rigorous, found significant effects of valerian on sleep. Overall, the evidence, while supporting that valerian is a safe herb associated with only rare adverse events, does not support the clinical efficacy of valerian as a sleep aid for insomnia.

---

### Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline [^111G1WEx]. Journal of Clinical Sleep Medicine (2017). Medium credibility.

Regarding nonpharmacologic interventions for insomnia, more specifically with respect to alternative and complementary medicine, AASM 2017 guidelines recommend to avoid using tryptophan or valerian for the treatment of sleep onset or sleep maintenance insomnia.

---

### The chronic effects of a combination of herbal extracts (euphytose) on psychological mood state and response to a laboratory stressor: a randomised, placebo-controlled, double blind study in healthy humans [^115XAxc1]. Journal of Psychopharmacology (2022). Medium credibility.

Herbal approaches to reduce anxiety may be as effective as pharmacological treatments and are less likely to be associated with adverse side effects. Several herbal species including Valeriana officinalis (valerian), Passiflora incarnata L. (passionflower) and Ballota nigra L. (ballota) have a long history of use as anxiolytics in traditional medicine, further supported by recent pre-clinical and clinical trials. For example, in vitro studies suggest that certain constituents of valerian can bind to and influence the activity of gamma-aminobutyric acid (GABA) A sites, the same sites influenced by benzodiazepines commonly used as prescribed anxiolytics. Valerian extract has also been found to influence the transport of GABA itself. While modulation of GABA receptors is thought to be one of the leading mechanisms of action of the plant, the extract has also demonstrated partial agonist activity at serotonin receptors as well as adenosine A₁ receptor signalling. In vivo, valerian has potent anxiolytic effects in rodents, with those administered valerian root extract showing significantly lower levels of anxiety than those administered a control substance. Valerian, in combination with Melissa officinalis (lemon balm), led to significantly lower levels of anxiety during laboratory-induced stress in humans. Here, individuals given a 600-mg dose reported significantly lower levels of anxiety than those given placebo or a higher 1800 mg dose. A similar dose in isolation (530 mg) significantly reduced state anxiety (as measure by the State-Trait Anxiety Inventory (STAI)) following 1 month's supplementation in haemodialysis patients. Anxiolytic effects have also been demonstrated following lower doses. Individuals administered with a 100-mg dose of valerian within a clinical setting, reported feeling subjectively calmer and less anxious compared to controls when receiving dental surgery. Similarly, 100 mg of valerian provided comfort and relaxation (in the absence of sedating effects) during molar extraction in anxious patients. Valerian has also led to increases in frontal alpha activity as measured by electroencephalogram (EEG) following a 300-mg daily dose for 1 month, a finding correlated with anxiolysis.

---

### Diazepam (Valium) [^111YgW84]. FDA (2025). Medium credibility.

DOSAGE AND ADMINISTRATION

Dosage should be individualized for maximum beneficial effect. While the usual daily dosages given below will meet the needs of most patients, there will be some who may require higher doses. In such cases dosage should be increased cautiously to avoid adverse effects.

Discontinuation or Dosage Reduction of Valium

To reduce the risk of withdrawal reactions, use a gradual taper to discontinue Valium or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly (see WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence).

---

### ACOG committee opinion no. 760: dysmenorrhea and endometriosis in the adolescent [^115yJUzh]. Obstetrics and Gynecology (2018). Medium credibility.

ACOG Committee Opinion — complementary and alternative therapies for dysmenorrhea advises that adolescents should be asked about alternative treatments they may already use, and there are promising, although limited, data on exercise and heat treatment; given low risk and cost, both options should be encouraged; limited-evidence supplements include fenugreek, ginger, valerian, zataria, zinc sulphate, fish oil, and vitamin B1; a study of adolescent girls with a mean age of 14.72 years found decreased prevalence of dysmenorrhea with high-dose vitamin D weekly for 9 weeks, although other studies show limited effect; transcutaneous electrical nerve stimulation, acupuncture, herbal preparations, and yoga have shown improvement in some studies, but current evidence does not support them as first-line complementary and alternative therapies; safety and efficacy data on herbal treatments are unclear.

---

### Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial [^116S6vEN]. Menopause (2011). Low credibility.

Objective

Sleep disturbances reduce the quality of life. About 50% of postmenopausal women experience sleep disturbances such as insomnia. Complementary and alternative medical therapies may be useful for the management of sleep disturbances among postmenopausal women. The aim of the present study was to evaluate the effects of valerian extract taken nightly on the improvement of sleep quality in postmenopausal women experiencing insomnia.

Methods

A randomized, triple-blind, controlled trial design was used for this study. Participants consisted of 100 postmenopausal women aged 50 to 60 years who were experiencing insomnia. A demographic data form and the Pittsburgh Sleep Quality Index were used to collect data. The women were randomly divided into two groups. Each group received either 530 mg of concentrated valerian extract or a placebo twice a day for 4 weeks. Descriptive and inferential statistics were used to analyze the data.

Results

A statistically significant change was reported in the quality of sleep of the intervention group in comparison with the placebo group (P < 0.001). Also, 30% of the participants in the intervention group and 4% in the placebo group showed an improvement in the quality of sleep (P < 0.001).

Conclusions

Valerian improves the quality of sleep in women with menopause who are experiencing insomnia. Findings from this study add support to the reported effectiveness of valerian in the clinical management of insomnia.

---

### The chronic effects of a combination of herbal extracts (euphytose) on psychological mood state and response to a laboratory stressor: a randomised, placebo-controlled, double blind study in healthy humans [^115gRqk2]. Journal of Psychopharmacology (2022). Medium credibility.

Discussion

In the current study, 14 days' supplementation with MHEP was associated with reduced tension-anxiety. In addition, participants showed an attenuated response to the OMS psychosocial stressor following MHEP, evidenced by lower salivary α-amylase and GSR. With regards to cognitive performance assessed at home via Cognim app, MHEP led to significantly fewer false alarms on the RVIP task compared with placebo. A significant reduction in speed of performance on the digit vigilance task following MHEP was also observed. However, this isolated negative effect was only observed during the morning assessment on day 7 and appears to contradict the pattern of response for the other assessments where performance was numerically faster following MHEP.

Concerning mood, tension-anxiety was significantly lower following MHEP, compared to placebo. The POMS questionnaire from which this measure is derived was completed prior to the start of the study day and therefore represents a reduction in tension-anxiety following 14 days' treatment. Of the species contained within the extract, both passionflower and valerian have demonstrated subjective anxiolytic properties within the literature following an acute, sometimes larger, dose of the individual extracts. Since the quantities of valerian and passionflower contained within the MHEP are in some cases lower than those previously observed to have anxiolytic effects, the improvement in subjective anxiety seen here may represent the cumulative effect of a smaller dose of each extract. In terms of mechanisms, the sesquiterpene valerenic acid contained within valerian (when extracted from the underground organs of the V. officinalis species as in MHEP) has been shown to increase central GABA levels. This leads to a reduction in central nervous system activity, which may have contributed to the reduction in tension-anxiety observed here following MHEP. It has been demonstrated that the ratio of valerenic acid to acetoxy valerenic acid contained within the extract is of importance in this regard, with extracts containing higher levels of valerenic acid leading to more pronounced anxiolytic effects. With regards to the Passiflora species, despite a long history of use as an anxiolytic, its mechanism of action is not well understood. A role of the flavonoid chrysin in the agonism of benzodiazepine receptors has been proposed; however, consensus here is lacking. Interestingly, the anxiolytic activity profile of the P. incarnata extract is reportedly determined by the parts of the plant used, with the roots shown to be devoid of anxiolytic effects and the leaves said to contain maximum concentrations of bioactive constituents. Importantly, the P. incarnata extract contained within MHEP is obtained from the aerial parts of the plant. It should be noted that this was an isolated effect on mood, and there was no evidence of a chronic effect of treatment on state or trait anxiety – the primary outcome measure – or any other of the mood measures. This positive effect, albeit in the expected direction, should therefore be interpreted with caution. One consideration here is the context in which the pre-dose mood and well-being questionnaires were administered. Participants completed these questionnaires and mood scales in full knowledge that they were going to complete the OMS, and this may have influenced their responses on these questionnaires. Subjective well-being has been shown to correlate with current mood and is also affected by experimental manipulation. It may be that that anticipation of the OMS masked any chronic effect of treatment on state anxiety or indeed any of the other subjective measures.

---

### Effect of valerian on cognitive disorders and electroencephalography in hemodialysis patients: a randomized, cross over, double-blind clinical trial [^114L8MWL]. BMC Nephrology (2018). Low credibility.

Complementary medicine has attracted further attentions among the various approaches to heal cognitive disorders. The name valerian, Valeriana officinalis, comes from the Latin word valere, meaning to be strong or healthy. Valerian contains 150 to 200 different substances, including volatile oils, ketones, and phenols, iridoid esters such as valreotriate, valric acid, alkaloids, and amino acids like aminobutric acid, tyrosine, arginine, glutamine and noncyclic, monocyclic and bicyclic hydrocarbons. This herbaceous perennial plant with short rhizomes creates underground creeping stem and is widely found in temperate regions of Asia, Europe and North America, and has beneficial properties for the heart, brain and stomach.

Valerian extract as an agonist of adenosine A1 receptors inhibits cholinergic transmission, increases the frequency strength of delta, theta and alpha waves in the frontal cortex and has sedative-like effects. Valerian has been considered as a sedative in Europe and then the United States since the 16th and 17th centuries and has been a part of the pharmacopoeia in Europe and America. The American Herbal Products Association (AHPA) categorized Valerian as Class I in terms of health and safety, and the US Food and Drug Administration has allowed its entry in food. Valerenic acid, as a sesquiterpenoid, is considered among the major secondary bioactive metabolites of Valeriana officinalis L. Until now, the number of in vivo studies on the absorption, bioavailability, disposition, and metabolism of Valerenic acid has been limited. Pharmacokinetics of Valerenic acid in rats after oral treatment has been also described by a two-compartment model with a clearance (CL/F) of 2–5 L/h/kg and a volume of distribution of 17–20 L/kg. The extent of the absorption after oral administration has been similarly estimated to be 33.70% with a half-life of 2.7–5 h. According to a study on valerian, different doses of this medication could cause no increase in blood urine nitrogen and creatinine (compared to sham group). Therefore, the extract of this herb was not likely to have toxic effects on rat kidneys.

---

### Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocket [^114zHKEe]. Nature Communications (2018). Medium credibility.

IVA has been quantified to be ~12% of the methanol extract of the Mallotus leaf extract. IVA is also a component of valerian root, an herbal medicine used since ancient Greek and Roman times to treat insomnia, and since medieval times in Europe specifically to treat seizures. Valerian root extract is still used extensively today for anxiety and insomnia, although randomized controlled trials evaluating its efficacy have achieved mixed results –. It has been estimated that 10 g of valerian root might yield as much as 100 mg of IVA, and that valerian root doses of 30–50 g per day would have the potential for anticonvulsant activity. Pharmacokinetic studies in humans have been performed for NPS 1776, or isovaleramide, the amide derivative of IVA. Isovaleramide readily passes though biological membranes, and is well tolerated in humans up to at least 2400 mg per day. Absorption is rapid (mean T max of 30–45 min) and mean elimination half-life is 2.5 h. Furthermore, volatile fatty acids similar to IVA, e.g. acetate, readily cross the blood brain barrier. Taken together, these studies together with our current findings suggest that herbal extracts contain sufficient bioavailable IVA to exert effects on KCNQ2/3 channels, particularly if synergizing with MTX.

Mutagenesis results indicating differential requirement of W236/W265 (Fig. 5g) suggest that MTX and IVA can sit together in the same binding pocket (Fig. 6j), a site we recently discovered evolved to accommodate neurotransmitters including GABA. When combined with the modern anticonvulsant RTG, the herbal extracts IVA and MTX have the unprecedented capacity to lock open KCNQ2/3 at all voltages tested, converting it into a voltage-independent leak channel. Our cellular electrophysiology and docking predictions support a mechanism for this: while RTG is a more potent agonist of KCNQ3 (refs.), IVA and MTX are more potent agonists of KCNQ2 (Figs. 2 and 5). Thus, the combination of either herbal component with RTG can leverage subunit heterogeneity in KCNQ2/3, a feature lacking in modern anticonvulsants, to increase synergy.

---

### Guideline no. 422c: menopause: mood, sleep, and cognition [^114p1dgN]. Journal of Obstetrics and Gynaecology Canada (2021). High credibility.

Regarding specific circumstances for insomnia, more specifically with respect to menopausal patients, SOGC 2021 guidelines recommend to consider offering CBT-I,
aerobic exercise, eszopiclone, venlafaxine, black cohosh, and valerian root to improve sleep.

---

### Effect of valerian on cognitive disorders and electroencephalography in hemodialysis patients: a randomized, cross over, double-blind clinical trial [^116qUZYJ]. BMC Nephrology (2018). Low credibility.

In this study, the changes in EEG were not significant in the two groups of A and B in the two one-month treatment periods. Diaper et al. (2004) studied the effects of two different concentrations of valerian on sleep, cognitive function and motor function in elderly people with sleep disorders. The results showed no significant difference between valerian 300 mg, 600 mg or placebo in EEG indices and psychometric measurements. Vonderheid-Guth et al. (2000) in Germany within a double-blind crossover study investigated the pharmacodynamic effects of different amounts of commercial valerian-hops extract mix on quantitative EEG topography (QEEG) in 12 young healthy volunteers compared to the placebo. The results showed that the EEG was able to show mild, but visible, effects especially after taking high concentrations of valerian-hops mix.

In this study, the reason for the insignificant changes in EEG before and after intervention might be attributed to inappropriate cooperation of patients with EEG. Some patients refused to perform EEG due to various works and time consuming during the intervention phase. The results of this study can be guidelines for designing new programs and using non-chemical methods to attenuate the cognitive disorders in patients undergoing hemodialysis, as well as can be a model for further researches regarding the examination of other Valerian properties and the use of complementary medicine.

---

### Effect of valerian in preventing neuropsychiatric adverse effects of efavirenz in HIV-positive patients: a pilot randomized, placebo-controlled clinical trial [^1128eQeM]. The Annals of Pharmacotherapy (2017). Low credibility.

Background

Several neuropsychiatric adverse effects of efavirenz are known. Preventing these adverse effects may improve patients' adherence to antiretroviral therapy (ART).

Objectives

To evaluate the efficacy and safety of valerian in preventing neuropsychiatric adverse effects of efavirenz in HIV-positive patients.

Method

In this pilot randomized, double-blinded, placebo-controlled, clinical trial, 51 HIV-positive patients who were receiving efavirenz were recruited into the valerian (n = 25) or placebo (n = 26) group. Patients received valerian (530 mg) or placebo nightly 1 hour before sleep for 4 weeks. The neuropsychiatric status (sleep, anxiety, depression, suicidal thought, and psychosis) of patients was assessed at baseline and week 4 using validated questionnaires.

Results

Sleep (P ≤ 0.001) and anxiety (P = 0.001) significantly improved in the valerian group compared with the placebo group. Dizziness was the most common complaint of patients in first days of the intervention. In the valerian and placebo groups, 92% and 84.6% of patients experienced dizziness, respectively (P = 0.35). Nausea was the second common adverse effect that 84% and 76.9% of patients in the valerian and placebo groups experienced (P = 0.39).

Conclusion

In the first 4 weeks of ART including efavirenz, valerian significantly improved sleep and anxiety in HIV-positive patients. Valerian may be considered as a potential option in preventing neuropsychiatric adverse effects of efavirenz in HIV-positive patients.

---

### VA / DoD clinical practice guideline for the management of chronic insomnia disorder and obstructive sleep apnea [^115gtQ2S]. VA/DoD (2025). High credibility.

Chronic insomnia — herbal supplements (chamomile, melatonin, passionflower, saffron, valerian): The Work Group systematically reviewed evidence and reported that these supplements did not show improvement in insomnia outcomes, are associated with side effects, and can delay appropriate insomnia treatment; the harms slightly outweighed the benefits and the Work Group decided on a Weak against recommendation. The Work Group's confidence in the quality of the evidence was very low, and the recommendation was categorized as Reviewed, Amended with no new evidence regarding chamomile, with limitations including small sample size, risk of bias, imprecision of data, and indirectness of data. Additional considerations noted that herbal supplements are not FDA regulated, there are concerns about purity and composition, costs can vary from cheap to expensive which can place an additional financial burden, melatonin has been associated with excessive daytime sleepiness, vivid dreams, and nightmares, and valerian has also been associated with liver toxicity; given these supplements were not shown to improve insomnia, choosing them over proven treatments could be detrimental to the patient.

---

### Valsartan (Diovan) [^111WkmoW]. FDA (2025). Medium credibility.

The dosage of valsartan PO for treatment of heart failure in adults is:

- **Start at**: 40 mg PO BID
- **Maintenance**: 80–160 mg PO BID
- **Maximum**: 320 mg per day

---

### VA / DoD clinical practice guideline for the management of chronic insomnia disorder and obstructive sleep apnea [^113kzutv]. VA/DoD (2025). High credibility.

Regarding nonpharmacologic interventions for insomnia, more specifically with respect to alternative and complementary medicine, DoD/VA 2025 guidelines recommend to avoid using chamomile, passionflower, saffron, or valerian for the treatment of chronic insomnia disorder.

---

### The chronic effects of a combination of herbal extracts (euphytose) on psychological mood state and response to a laboratory stressor: a randomised, placebo-controlled, double blind study in healthy humans [^114AWeap]. Journal of Psychopharmacology (2022). Medium credibility.

With regards to the physiological measures collected during the OMS procedure, an increase in the electrodermal skin conductance response (measured in µSiemens) is recognised as a good indicator of activation of the sympathetic nervous system. The observed attenuation of this response during performance of the OMS following MHEP compared to placebo is therefore an indicative of a beneficial effect of the treatment. Similarly, a reduction in salivary α-amylase was also observed across the study day following MHEP. Salivary α-amylase is considered a valid measure of autonomic nervous system (ANS) activation, a reduction of which would also indicate an attenuation of the stress response. Euphytose has been shown to interact with benzodiazepine receptors, which has been proposed as the potential mechanism for its anxiolytic effects. Previously valerian has been shown to reduce HR during a mentally stressful cognitive task following 7 days administration, a finding not replicated in the present study following 14 days administration. However, this was following a considerably larger dose of 600 mg, as compared to the 300 mg daily dose contained within the MHEP. Similarly, an acute 260 mg dose of passionflower was observed to have the same effect on HR as the drug Midazolam, when administered prior to tooth extraction surgery, but, again, this is a larger dose than the 80 mg administered acutley here. Taking into consideration the quantities of each extract contained within MHEP, it is possible that skin conductance and salivary α-amylase are more sensitive to the effects of the lower doses administered here.

---

### Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline [^114owGtg]. Journal of Clinical Sleep Medicine (2017). Medium credibility.

American Academy of Sleep Medicine clinical practice guideline — agents suggested against for adults with chronic insomnia are as follows: We suggest that clinicians not use trazodone as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK) We suggest that clinicians not use tiagabine as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK) We suggest that clinicians not use diphenhydramine as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (WEAK) We suggest that clinicians not use melatonin as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK) We suggest that clinicians not use tryptophan as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK) We suggest that clinicians not use valerian as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK)

---

### Effect of valerian on cognitive disorders and electroencephalography in hemodialysis patients: a randomized, cross over, double-blind clinical trial [^114TgrCR]. BMC Nephrology (2018). Low credibility.

Scientific studies on valerian have begun on humans since 1970. Vonderheid-Guth et al. (2000) argue that the use of valerian-hops mix has pharmacodynamic responses in the brain. Schulz et al. (1998) in two multiple crossover studies, each involving 12 adult female subjects, screened for acute sedative effects of eight different plant extracts. Valerian extract, which was administered in both studies, displayed an increase of power in the delta and theta bands and a decrease in the beta band. The results correspondingly showed that sedating effects of plant extracts could be identified by quantitative EEG analysis as well as self-assessment instruments. In addition, Hasani et al. (2013) has suggested valerian as a prophylactic strategy for the prevention of cognitive disorders after heart surgery.

Since cognitive disorders are common in hemodialysis patient, the severity and characteristics of them are not well defined, which are associated with prolonged hospitalization, poor quality of life, mortality and morbidity among the hemodialysis patients. On the other hand, cognitive disorders have more serious consequences; for example, lowering life expectancy that might prevent the hemodialysis patients participating in the hemodialysis programs, taking medications and adhering to dietary restrictions. Therefore, it is essential to investigate the cognitive disorders and control the related complications in order to achieve better therapeutic outcomes in these patients. Considering the effects of valerian extract on brain wave in EEG and its possible role in improving cognitive disorders, we decided to evaluate the effect of valerian on cognitive disorders and EEG in the hemodialysis patients.

---

### Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both [^117Db9tk]. Clinical Therapeutics (2004). Low credibility.

Background

Recent data suggest that use of relatively high doses of angiotensin II-receptor blockers (ARBs) in hypertensive patients at high cardiovascular risk may reduce the incidence of clinical complications to a greater extent than would be predicted based on blood-pressure (BP) lowering alone. There is also evidence that a sustained reduction in BP, however small, may be important in reducing the risk of cardiovascular disease. Therefore, it is necessary to determine the ARB dosages that optimize the efficacy/tolerability ratio.

Objective

This article reviews experimental and clinical studies of the ARB valsartan to define the daily dose that provides the best ratio between efficacy and tolerability in patients with hypertension, heart failure, or both.

Methods

Relevant studies were identified through searches of EMBASE and Science Citation Index for articles published before December 15, 2003. No language restrictions were applied. Search terms were angiotensin II-receptor blockers, cardiovascular disease, hypertension, heart failure, type 2 diabetes mellitus, and angiotensin-converting enzyme inhibitors.

Results

In several randomized, double-blind, dose-finding studies, the antihypertensive effect of valsartan increased in a predictable fashion over a wide dose range (20–320 mg). The antihypertensive efficacy of the 80-mg dose was enhanced by doubling it to 160 mg, and the tolerability profile remained comparable to that of placebo over a broad dose range. Valsartan has been investigated in patients with heart failure at dosages ranging from 40 to 160 mg BID. Because of the need for careful individualization of therapy in these patients, rigid dose standardization may not be appropriate.

Conclusions

Based on the efficacy/tolerability profile of valsartan at various doses, it appears that 160 mg may be the optimal dose for initial therapy in patients with essential hypertension and in most patients with heart failure.

---

### Guideline no. 422c: menopause: mood, sleep, and cognition [^116S675a]. Journal of Obstetrics and Gynaecology Canada (2021). High credibility.

Regarding medical management for menopause, more specifically with respect to management of sleep disorders, SOGC 2021 guidelines recommend to consider offering CBT-I,
aerobic exercise, eszopiclone, venlafaxine, black cohosh, and valerian root to improve sleep.

---

### Herbal medicine for insomnia: a systematic review and meta-analysis [^113BbYK3]. Sleep Medicine Reviews (2015). Low credibility.

Insomnia is a prevalent sleep disorder that can profoundly impact a person's health and wellbeing. Herbal medicine represents one of the most frequently used complementary and alternative treatments of insomnia. However, the safety and efficacy of herbal medicine for the treatment of this disorder is currently uncertain. In order to ascertain the evidence base for herbal medicine for insomnia, we systematically searched seventeen electronic databases and the reference lists of included studies for relevant randomised controlled trials (RCTs). Fourteen RCTs, involving a total of 1602 participants with insomnia, met the inclusion criteria. Four distinct orally administered herbal monopreparations were identified (i.e., valerian, chamomile, kava and wuling). There was no statistically significant difference between any herbal medicine and placebo, or any herbal medicine and active control, for any of the thirteen measures of clinical efficacy. As for safety, a similar or smaller number of adverse events per person were reported with kava, chamomile and wuling when compared with placebo. By contrast, a greater number of events per person were reported with valerian. While there is insufficient evidence to support the use of herbal medicine for insomnia, there is a clear need for further research in this area.

---

### Deciding the dose to prescribe [^111JMBtc]. Drug and Therapeutics Bulletin (2004). Low credibility.

The dose of a medicine prescribed is so much a part of everyday practice and prescribing guidance that it might appear a surprising subject for a symposium. In reality, however, many questions about choosing doses are unresolved. Here we summarise the talks given at our March 2004 symposium — Deciding the dose to prescribe — incorporating views raised in discussion.

---

### Guidelines for monitoring and management of pediatric patients before, during, and after sedation for diagnostic and therapeutic procedures: update 2016 [^114hXy1d]. Pediatrics (2016). Medium credibility.

Pediatric sedation — medication and supplement interactions and analgesia caution note that many agents may "interfere with drug absorption or metabolism and therefore enhance or shorten the effect time of sedating medications", including herbal medicines such as "St John's wort, ginkgo, ginger, ginseng, garlic" that "may alter drug pharmacokinetics through inhibition of the cytochrome P450 system" affecting midazolam and others; "Kava may increase the effects of sedatives" and "may increase acetaminophen-induced liver toxicity", "Valerian may itself produce sedation", and drugs such as "erythromycin, cimetidine" may inhibit the cytochrome P450 system, with additional interactions from "medications used to treat HIV infection, some anticonvulsants, immunosuppressive drugs, and some psychotropic medications"; therefore, "a careful drug history is a vital part of the safe sedation of children", "the practitioner should consult various sources" for interaction information, and due to a regulatory warning "codeine should be avoided for postprocedure analgesia" after tonsillectomy in children.

---

### Practice guideline summary: treatment of restless legs syndrome in adults: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology [^116hge6b]. Neurology (2016). Medium credibility.

Regarding medical management for restless legs syndrome, more specifically with respect to agents with no evidence for benefit, AAN 2016 guidelines recommend to insufficient evidence to recommend for or against the use of gabapentin, iron sucrose, oxycodone, clonazepam, bupropion, clonidine, selenium, rifaximin, botulinum neurotoxin, valproic acid, carbamazepine, or valerian in the treatment of RLS.

---

### Valganciclovir [^1144oEcC]. FDA (2024). Medium credibility.

Regarding the use of valganciclovir hydrochloride PO in patients with eGFR 25–39 mL/min/1.73 m²:
- Maximal dose of 450 mg. Do not exceed frequency of once daily.
- Monitor complete blood count. Monitor platelet counts.
- An alternative treatment regimen
GFR (mL/min) Dose
> 50 900 mg twice daily

25–50 450 mg twice daily
10–25 450 mg once daily
 < 10 450 mg 3 times a week.

---

### Valganciclovir [^111Po2Mu]. FDA (2024). Medium credibility.

Regarding the use of valganciclovir hydrochloride PO in patients with eGFR 40–59 mL/min/1.73 m²:
- Maximal dose of 450 mg. Do not exceed frequency of BID.
- Monitor complete blood count. Monitor platelet counts.
- An alternative treatment regimen
GFR (mL/min) Dose
> 50 900 mg twice daily

25–50 450 mg twice daily
10–25 450 mg once daily
 < 10 450 mg 3 times a week.

---

### Valganciclovir [^115WH7WA]. FDA (2024). Medium credibility.

Regarding the use of valganciclovir hydrochloride PO in patients with eGFR < 10 mL/min/1.73 m²:
- Maximal dose of 450 mg. Do not exceed frequency of 2–3× per week.
- Monitor complete blood count. Monitor platelet counts.
- An alternative treatment regimen
GFR (mL/min) Dose
> 50 900 mg twice daily

25–50 450 mg twice daily
10–25 450 mg once daily
 < 10 450 mg 3 times a week.

---

### Valerian… [^113kNQaM]. AAFP (2003). Low credibility.

4 In a double-blind study, 5 eight subjects who described themselves as having lengthy sleep latency wore a wrist activity meter and provided subjective sleep ratings in a study of the effects of valerian. Participants received either a 450- or 900-mg dose of an aqueous extract of valerian root or placebo. Single-dose valerian extract resulted in significant decreases in measured and subjective sleep latency and more stable sleep during the first quarter of the night, with no effect on total sleep time. The 900-mg dose produced increased sleepiness on awakening compared with placebo. A randomized, placebo-controlled, double-blind, cross-over study 6 involving 16 patients with insomnia confirmed by polysomnography demonstrated no effects on sleep efficiency after a single 600-mg dose of the valerian extract Sedonium, while multiple doses over 14 days resulted in significant improvement in parameters of slow-wave sleep measured by polysomnography.

There was a nonsignificant trend toward reduced subjective sleep latency after the long-term valerian treatment.
6. In a recent preliminary, randomized, double-blind, placebo-controlled trial, 16 36 patients with a diagnosis of generalized anxiety disorder were treated with placebo, diazepam in a dosage of
2. 5 mg three times daily, or valerian extract in a dosage of 50 mg three times daily for four weeks. 1, 20 Valerian may potentiate the sedative effects of barbiturates, anesthetics, and other central nervous system depressants. 21 One case report 22 suggests that sudden cessation of long-term high dose valerian therapy may result in withdrawal symptoms similar to those occurring with benzodiazepine use.

Perhaps because of the poorly defined effects of valerian on GABA neurotransmission, valerian appears to attenuate benzodiazepine withdrawal symptoms in animals and humans. 23, 24. Dosage Based on the reviewed studies, the effective dosage of valerian root extract for treatment of insomnia ranges from 300 to 600 mg. An equivalent dose of dried herbal valerian root is 2 to 3 g, soaked in one cup of hot water for 10 to 15 minutes. 25 The product should be ingested 30 minutes to two hours before bedtime.

---

### Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocket [^1132tqfp]. Nature Communications (2018). Medium credibility.

Fig. 5
IVA activates neuronal KCNQs with preference for KCNQ2. a Left, Valeriana officinalis. Right, structure (upper) and electrostatic surface potential (red, negative; blue, positive) (lower) of isovaleric acid (IVA). b Binding position of IVA in KCNQ3 predicted by SwissDock using a chimeric KCNQ1–KCNQ3 structure model. c Mean tail current versus prepulse voltage relationships recorded by TEVC in Xenopus laevis oocytes expressing homomeric KCNQ1–5 channels in the absence (black) and presence (blue) of IVA (n = 4–7). Voltage protocol as in Fig. 1d. d IVA dose response at −60 mV for KCNQ2–5, quantified from data as in c (n = 4–7). e Mean tail current versus prepulse voltage relationships for wild-type KCNQ2/3 (left) or KCNQ2-W236L/KCNQ3-W265L (right) channels in the absence or presence of IVA as indicated (n = 4–6). Voltage protocol as in Fig. 1d. f Dose response for current increase at −60 mV in response to IVA for channels as in e.g. Dose response for the V 0.5 of activation shift induced by IVA versus MTX in wild-type KCNQ2/3 versus KCNQ2-W236L/KCNQ3-W265L (WL/WL) channels. IVA data (n = 4–6) quantified from e; MTX data from Fig. 3d. h Averaged traces for KCNQ1 in the absence or presence of IVA (500 µM); n = 6. i Mean data from traces as in h. j Exemplar traces showing effects of IVA (500 µM) with GABOB (100 µM) on KCNQ2/3 channels. Voltage protocol as in Fig. 1d. k Effects of IVA (500 µM) with GABOB (100 µM) on mean tail current (left) and G/G_max (right) relationships for KCNQ2/3 (n = 5) calculated from traces as in panel j. l Current fold-change at −60 mV exerted by IVA (500 µM) alone (from panel f) or with 100 µM GABOB, from data as in panel k (n = 5). m Right, dose responses for the shift in V₀.₅ of KCNQ2/3 activation induced by the leaf extract compounds shown on left, calculated from traces as shown in Figs 1, 2 and 5 (n = 4–16). All error bars indicate SEM

---

### Valganciclovir [^116pXEbT]. FDA (2024). Medium credibility.

Regarding the use of valganciclovir hydrochloride PO in patients with eGFR 10–24 mL/min/1.73 m²:
- Maximal dose of 450 mg. Do not exceed frequency of q48h.
- Monitor complete blood count. Monitor platelet counts.
- An alternative treatment regimen
GFR (mL/min) Dose
> 50 900 mg twice daily

25–50 450 mg twice daily
10–25 450 mg once daily
 < 10 450 mg 3 times a week.

---

### Assessment of valeriana officinalis L. (valerian) for conscious sedation of patients during the extraction of impacted mandibular third molars: a Randomized, split-mouth, double-blind, crossover study [^111y8ZY7]. Journal of Oral and Maxillofacial Surgery (2019). Medium credibility.

Purpose

The objective of the present study was to evaluate the effectiveness of an herbal drug (valerian) to control anxiety during mandibular third molar extraction compared with a reference benzodiazepine drug commonly used in dental procedures (midazolam).

Materials and Methods

Twenty anxious patients with an indication for bilateral extraction of mandibular third molars were selected. The patients received capsules containing valerian 100 mg or midazolam 15 mg orally 60 minutes before the procedures in a randomized, split-mouth, crossover design. Changes in the physiological parameters (eg, oxygen saturation, heart rate, blood pressure, respiratory rate) were assessed at specific times during surgery, and the patients completed a questionnaire postoperatively. The data were analyzed using the Wilcoxon and paired t tests, with a significance level of 5%.

Results

No statistically significant differences in oxygen saturation were observed, regardless of the drug used. However, the other physiological parameters were significantly lower when the patients had taken midazolam compared with valerian. Somnolence was the most common side effect reported with both drugs.

Conclusions

Although midazolam was more effective in reducing the physiological parameters studied, valerian seemed to provide the comfort and relaxation required, with no sedation and less somnolence than midazolam, during third molar extraction. Further studies are necessary before valerian can be clinically recommended.

---

### Valganciclovir [^112iV1Lt]. FDA (2024). Medium credibility.

Regarding the use of valganciclovir hydrochloride PO in patients with eGFR 40–59 mL/min/1.73 m²:
- Maximal dose of 450 mg. Do not exceed frequency of once daily.
- Monitor complete blood count. Monitor platelet counts.

---

### Valganciclovir [^111FFGko]. FDA (2024). Medium credibility.

Regarding the use of valganciclovir hydrochloride PO in patients with continuous renal replacement:

- Dose as in eGFR 10–24 mL/min/1.73 m². Maximal dose of 450 mg. Maximal frequency of 2× per week.
- Monitor complete blood count. Monitor platelet count.

---

### Valganciclovir [^117Tx5L2]. FDA (2024). Medium credibility.

Regarding the use of valganciclovir hydrochloride PO in patients with eGFR 25–39 mL/min/1.73 m²:
- Maximal dose of 450 mg. Do not exceed frequency of q48h.
- Monitor complete blood count. Monitor platelet counts.

---

### Valganciclovir [^1117CjvP]. FDA (2024). Medium credibility.

Regarding the use of valganciclovir hydrochloride PO in patients with eGFR 10–24 mL/min/1.73 m²:
- Maximal dose of 450 mg. Do not exceed frequency of 2× per week.
- Monitor complete blood count. Monitor platelet counts.

---

### Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability [^117Be3J7]. Journal of Psychopharmacology (2005). Low credibility.

A number of medicinal plants are traditionally endowed with anxiolytic or sedative properties and, in the context of this revue, both indications are considered since the former may induce a mood conducive to the latter. For any sleep-inducing drug to be effective, a tranquil ambience needs to be established a priori. Thus, physical ailments (i.e. pain), factors interfering with sleep (i.e. noise), psychological conditions causing stress, psychiatric illnesses (i.e. depression) and other drugs that interfere with sleep (i.e. caffeine) need to be controlled, if possible. Kava-kava is a well-established hypnotic drug, with a rapid onset of effect, adequate duration of action and minimal morning after-effects. However, reports of serious hepatotoxicity with this preparation have led to it being banned in most countries worldwide. On the other hand, side-effects with valerian would appear to be bland indeed. However, it's slow onset of effect (2–3 weeks) renders it unsuitable for short-term use (i.e. 'jet-lag'), but it does have profound beneficial effects on sleep architecture (augments deep sleep) that may make it particularly suitable for long-term use and for the elderly. In a personal trial (not double-blind) in stress-induced insomnia, both kava and valerian improved sleep and the ill-effects of stress, and the combination of the two was even more effective for the control of insomnia. Aromatherapy (lavender, chamomile, Ylang-Ylang) would appear to improve sleep, but how practical a form of treatment this may be remains to be determined. The only other plant drug that may have some effect on sleep is melissa, but reports are too scanty to form any opinion about this. Based on animal experiments, passion flower (passiflora) may have a sedative action, but the sedative action of hops has not been investigated in any detail. In conclusion, there is a need for longer-term controlled studies with some of these compounds (particularly valerian). Aromatherapy constitutes a tantalising possibility. In the interpretation of this review, it should be borne in mind that the evidence on which it is based is often incomplete or missing, but that is all that is available. Consequently some conjecture on the part of the author is inevitable and should be appreciated as such.

---

### Valganciclovir [^111K9pFi]. FDA (2024). Medium credibility.

Regarding the use of valganciclovir hydrochloride PO in patients with continuous renal replacement:

- Dose as in eGFR 10–24 mL/min/1.73 m². Maximal dose of 450 mg. Maximal frequency of q48h.
- Monitor complete blood count. Monitor platelet count.

---

### Effect of valerian on cognitive disorders and electroencephalography in hemodialysis patients: a randomized, cross over, double-blind clinical trial [^113atdq8]. BMC Nephrology (2018). Low credibility.

Table 1
Participant's characteristics in the groups under study

a The group A took valerian capsules in the first therapeutic period of one month and placebo in the second therapeutic period of one month, and vice versa in group B

The total score of MMSE in the Group valerian was increased significantly in the first month (P = 0.003) and the second month (P = 0.005) of treatment. The scores of concentration and calculation subscales in the Group valerian were increased significantly in both periods (P = 0.014). Such an increase was also observed in the memory subscale in the first one-month (P = 0.014) and the second one-month (P = 0.46) periods. In other subscales, no significant increase was seen in any of the groups (Table 2).

Table 2
Mean and SD of cognitive scores groups A and B in first and second periods

a The group A took valerian capsules in the first therapeutic period of one month and placebo in the second therapeutic period of one month, and vice versa in group B

In the comparison of the two groups, only the difference in the increased total MMSE score between the two groups in both one-month periods was significant, so that the mean increased MMSE score during the first one-month treatment period was 1.32 ± 1.38 in the Group valerian and 0.35 ± 0.81 in the Group placebo. There was a significant difference in the distribution of scores between the two groups (P = 0.028). In the second one-month treatment period, the mean increased total MMSE score was 1.00 ± 1.17 in the Group valerian and 0.12 ± 0.78 in the Group placebo. There was a significant difference in the distribution of scores (P = 0.030), so that the increased MMSE score was more in the Group valerian in both periods (Table 3).

---

### Review of safety and efficacy of sleep medicines in older adults [^116F41KQ]. Clinical Therapeutics (2016). Low credibility.

Purpose

Insomnia is problematic for older adults. After behavioral modifications fail to show adequate response, pharmacologic options are used. The pharmacokinetics of agents used to treat insomnia may be altered. This review focuses on the safety and efficacy of medications used to treat insomnia.

Methods

A literature search of Medline, PubMed, and Embase was conducted (January 1966-June 2016). It included systematic reviews, randomized controlled trials, observational studies, and case series that had an emphasis on insomnia in an older population. Search terms included medications approved by the US Food and Drug Administration for insomnia: benzodiazepines (triazolam, estazolam, temazepam, flurazepam, and quazepam), nonbenzodiazepine receptor agonists (non-BzRAs; zaleplon, zolpidem, and eszopiclone), suvorexant, ramelteon, doxepin and trazodone. Off-label drugs such as other antidepressants, antihistamines, antipsychotics, gabapentin, pramipexole, tiagabine, valerian, and melatonin were also included.

Findings

Cognitive behavioral therapy and sleep hygiene are considered initial therapy for insomnia. Benzodiazepines are discouraged in the geriatric population, especially for long-term use. Although non-BzRAs have improved safety profiles compared with benzodiazepines, their side effects include dementia, serious injury, and fractures, which should limit their use. Ramelteon has a minimal adverse effect profile and is effective for sleep-onset latency and increased total sleep time, making it a valuable first-line option. Although the data on suvorexant are limited, this drug improves sleep maintenance and has mild adverse effects, including somnolence; residual daytime sedation has been reported, however. Sedating low-dose antidepressants should only be used for insomnia when the patient has comorbid depression. Antipsychotic agents, pramipexole, and tiagabine have all been used for insomnia, but none has been extensively studied in an older population, and all have considerable adverse effects. Gabapentin may be useful in patients with restless leg syndrome or chronic neuropathic pain and insomnia. Diphenhydramine should be avoided in the elderly. Valerian and melatonin are unregulated products that have a small impact on sleep latency and can produce residual sedation.

Implications

An ideal treatment for insomnia should help to improve sleep latency and sleep duration with limited awakenings and be without significant adverse effects such as daytime somnolence or decreased alertness. Cognitive behavioral therapy should always be first line treatment. Clinical inertia regarding previous prominent use of benzodiazepines and non-BzRAs will be a significant challenge for patients accustomed to their issuance. The future direction of insomnia treatment should have an emphasis on nonpharmacologic interventions, treating comorbid conditions, and focusing therapy on using benzodiazepines and non-BzRAs as last resorts.

---

### Cardiac complications and delirium associated with valerian root withdrawal… [^113CH4Fw]. JAMA Network (1998). Excellent credibility.

Margaret A. WinkerMD, Senior EditorIndividualAuthorPhil B. FontanarosaMD, Senior EditorIndividualAuthor. To the Editor. — Valerian root is a widely used herbal product with putative sedative, hypnotic, and anxiolytic benefits1-4 similar to the benzodiazepines. Preparations recommend dosages ranging from 200 mg to several grams per day taken at bedtime or in divided doses. The optimal duration of use is not well established, although some preparations advise against long-term use. We report a case of serious cardiac complications and delirium associated with withdrawal of valerian root. Garges HP, Varia I, Doraiswamy PM. Cardiac Complications and Delirium Associated With Valerian Root Withdrawal. JAMA. 1998; 280: 1566–1567. doi: 10–1001/pubs.JAMA-ISSN-0098-7484-280-18-jbk1111 © 2025 JAMA+ AI Customize your JAMA Network experience by selecting one or more topics from the list below.

---

### Valganciclovir [^117EW2W9]. FDA (2024). Medium credibility.

Regarding the use of valganciclovir hydrochloride PO in patients with eGFR < 10 mL/min/1.73 m²:
- Maximal dose of 450 mg. Do not exceed frequency of 1–2× per week.
- Monitor complete blood count. Monitor platelet counts.

---

### Estradiol valerate (Delestrogen) [^111CZ9o9]. FDA (2024). Medium credibility.

The dosage of estradiol valerate IM for treatment of hypoestrogenism in female adults (due to hypogonadism, due to primary ovarian failure, due to castration) is 10–20 mg IM q4 weeks

---

### Herbal medicines in pediatric neuropsychiatry [^114v3eE6]. Pediatric Clinics of North America (2011). Low credibility.

An increasing number of studies have evaluated the role of herbal supplements in pediatric disorders, but they have numerous limitations. This review provides an overview of herbal components, regulation of supplements, and importance of product quality assurance. Use of herbal supplements is discussed with reference to factors that influence use in the pediatric population. The remainder of the article discusses the use of St John's wort, melatonin, kava, valerian, eicosapentaenoic acid, and docosahexaenoic acid, focusing on indications, adverse effects, and drug interactions, and providing a limited efficacy review. Herbal supplements used for weight loss are also briefly discussed.

---

### Grading disorder severity and averted burden by access to treatment within the GBD framework: a case study with anxiety disorders [^113uRwxQ]. The Lancet: Psychiatry (2023). High credibility.

Estimation of treatment effects

Data on the efficacy of health-care interventions were sourced from the Cochrane Database of Systematic Reviews. A title and abstract keyword search was done for anxiety disorders ("anxiety disorder" OR "anxiety disorders") on April 27, 2022. Titles and abstracts were screened to determine which reviews to include. Reviews that did not assess an intervention for anxiety disorders; focused on non-standard or not recommended interventions (eg, valerian and antipsychotics); or focused on interventions for children, adolescents, or non-representative subpopulations (eg, women with breast cancer) were excluded. All remaining reviews were full-text screened and data for studies with outcomes relevant to disorder severity on a continuous scale were extracted. Data on intervention type, comparison type, follow-up duration, sample size, outcome mean, and outcome SD were extracted from each review.

---

### Effect of valerian on cognitive disorders and electroencephalography in hemodialysis patients: a randomized, cross over, double-blind clinical trial [^1155Gkq4]. BMC Nephrology (2018). Low credibility.

Table 3
Mean difference of cognitive scores before and after intervention in each treatment periods in the groups

a The group A took valerian capsules in the first therapeutic period of one month and placebo in the second therapeutic period of one month, and vice versa in group B

During the first one-month treatment period before the intervention, the EEG was determined for seven patients in the Group A and for eight cases in the Group B; one from the Group B did not cooperate after the intervention. In the second one-month treatment period before the intervention, seven patients in each group collaborated, but after the intervention, only six from Group A and three from Group B continued to cooperate.

In the first one-month treatment period, three out of seven were normal before and after intervention and three had a mild EEG problem before and after intervention. Only one had a mild problem before the intervention, which became normal after intervention; but the changes were not significant (P = 1.00). In the Group B, 3 out of 7 people with clear EEG status before and after the intervention had mild problem before intervention, which was mild after the intervention as well, but three people had mild impairment before intervention, which became normal after intervention; one person was normal before intervention that became mild after intervention. The changes were not significant (P = 0.625).

In the second one-month treatment period, two out of six in the Group A with detected EEG status had normal status before and after intervention, and one person had a mild state before and after intervention. However, two subjects had a mild state before intervention and became normal after intervention, but one had inversed status who was normal before the intervention and was mild after the intervention; the changes were not significant (P = 1.00). In the Group B, of three subjects whose EEG status was determined before and after intervention, two patients were normal before the intervention and one was mild, which all three were normal after intervention (Table 4).

Table 4
EEG and type of brain waves of hemodialysis patients before and after in treatments cycles

a The group A took valerian capsules in the first therapeutic period of one month and placebo in the second therapeutic period of one month, and vice versa in group B

---

### Valsartan (Diovan) [^112aA82J]. FDA (2025). Medium credibility.

The dosage of valsartan PO for treatment of left ventricular dysfunction in adults with myocardial infarction is:

- **Start at**: 20 mg PO BID initiated as early as 12 hours after myocardial infarction
- **Maintenance**: 160 mg PO BID

---

### Common herbal dietary supplement-drug interactions [^114U6dZQ]. American Family Physician (2017). Low credibility.

Nearly 25% of U.S. adults report concurrently taking a prescription medication with a dietary supplement. Some supplements, such as St. John's wort and goldenseal, are known to cause clinically important drug interactions and should be avoided by most patients receiving any pharmacologic therapy. However, many other supplements are predicted to cause interactions based only on in vitro studies that have not been confirmed or have been refuted in human clinical trials. Some supplements may cause interactions with a few medications but are likely to be safe with other medications (e.g., curcumin, echinacea, garlic, Asian ginseng, green tea extract, kava kava). Some supplements have a low likelihood of drug interactions and, with certain caveats, can safely be taken with most medications (e.g., black cohosh, cranberry, ginkgo, milk thistle, American ginseng, saw palmetto, valerian). Clinicians should consult reliable dietary supplement resources, or clinical pharmacists or pharmacologists, to help assess the safety of specific herbal supplement-drug combinations. Because most patients do not disclose supplement use to clinicians, the most important strategy for detecting herb-drug interactions is to develop a trusting relationship that encourages patients to discuss their dietary supplement use.

---

### In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4 / 5 phenotypes [^114GNVWN]. Clinical Pharmacology and Therapeutics (2005). Low credibility.

Objectives

Phytochemical-mediated modulation of cytochrome P450 (CYP) activity may underlie many herb-drug interactions. Single-time point phenotypic metabolic ratios were used to determine whether long-term supplementation of goldenseal (Hydrastis canadensis), black cohosh (Cimicifuga racemosa), kava kava (Piper methysticum), or valerian (Valeriana officinalis) extracts affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4/5 activity.

Methods

Twelve healthy volunteers (6 women) were randomly assigned to receive goldenseal, black cohosh, kava kava, or valerian for 28 days. For each subject, a 30-day washout period was interposed between each supplementation phase. Probe drug cocktails of midazolam and caffeine, followed 24 hours later by chlorzoxazone and debrisoquin (INN, debrisoquine), were administered before (baseline) and at the end of supplementation. Presupplementation and postsupplementation phenotypic trait measurements were determined for CYP3A4/5, CYP1A2, CYP2E1, and CYP2D6 by use of 1-hydroxymidazolam/midazolam serum ratios (1-hour sample), paraxanthine/caffeine serum ratios (6-hour sample), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour sample), and debrisoquin urinary recovery ratios (8-hour collection), respectively. The content of purported "active" phytochemicals was determined for each supplement.

Results

Comparisons of presupplementation and postsupplementation phenotypic ratio means revealed significant inhibition (approximately 40%) of CYP2D6 (difference, -0.228; 95% confidence interval [CI] -0.268 to -0.188) and CYP3A4/5 (difference, -1.501; 95% CI, -1.840 to -1.163) activity for goldenseal. Kava produced significant reductions (approximately 40%) in CYP2E1 only (difference, -0.192; 95% CI, -0.325 to -0.060). Black cohosh also exhibited statistically significant inhibition of CYP2D6 (difference, -0.046; 95% CI, -0.085 to -0.007), but the magnitude of the effect (approximately 7%) did not appear to be clinically relevant. No significant changes in phenotypic ratios were observed for valerian.

Conclusions

Botanical supplements containing goldenseal strongly inhibited CYP2D6 and CYP3A4/5 activity in vivo, whereas kava inhibited CYP2E1 and black cohosh weakly inhibited CYP2D6. Accordingly, serious adverse interactions may result from the concomitant ingestion of goldenseal supplements and drugs that are CYP2D6 and CYP3A4/5 substrates. Kava kava and black cohosh may interact with CYP2E1 and CYP2D6 substrates, respectively. Valerian appears to be less likely to produce CYP-mediated herb-drug interactions.

---

### Effect of valerian on cognitive disorders and electroencephalography in hemodialysis patients: a randomized, cross over, double-blind clinical trial [^115cCdkF]. BMC Nephrology (2018). Low credibility.

Discussion

The main findings of this study revealed that valerian could be effective and significantly improve cognitive status although no significant changes were observed in the EGG of the hemodialysis patients. The MMSE scores in the valerian group within the first and the second one-month treatment periods had also significantly increased. In line with these results, Hassani et al. (2013) in Sari, Iran, examined the effects of valerian root extract on early prevention of the postoperative cognitive disorders after coronary artery bypass graft surgery. They conducted a standardized MMSE on the day before surgery, 10 days and 2 months after surgery. A significant reduction in the cognitive disorders was seen in the Group valerian compared to the Group placebo within 10 days after surgery and a greater improvement in cognitive function within eight weeks after surgery. Ceddia et al. (2015) in the United States showed that the extract of herbs from the peppermint family also has a positive effect on cognitive health, including improvement in memory, reasoning, attention, concentration, planning and mood. In the study by Hensel et al. (2007), at least 2–4 points indicated that the reliable changes in the MMSE scores were clinically significant. In the present study, the results showed that valerian could significantly increase the overall cognitive scores of hemodialysis patients (between 0.88 and 0.97). More examples were similarly suggested for the sub-quantifiers that were not significant probably due to the limited time period of the study as well as different times considered for the evaluation of the MMSE scores in morning, evening, and night shifts.

In this study MMSE was completed the first hour of hemodialysis and then the EEG was done in the morning shift on the day after hemodialysis between 8 AM until 12 MD. Drew et al. (2015) also performed cognitive testing during hemodialysis, which in theory may influence cognitive performance through fluid shifts and changes in electrolyte levels. Drew et al. (2013) previously conducted a randomized crossover study in hemodialysis patients found no difference in performance based on the timing of testing. Also, the results of the study by Sperschneider et al. (1980) in Germany showed that changes in EEG remained constant or increased during the hemodialysis period. Also, Wendland and Susantija (1983) in assessment of EEG in the hemodialysis patients before and after hemodialysis, in 10 men and 11 women, showed that an increase in abnormal waves after hemodialysis. The changed of EEG was lower on the day after hemodialysis treatment.

---

### Diazepam (Valtoco) [^11185EVm]. FDA (2025). Medium credibility.

2 DOSAGE AND ADMINISTRATION

Administer VALTOCO by the nasal route only. (2.3)
Dosage is dependent on the patient's age and weight. (2.2)
Initial Dose: VALTOCO 5 mg and 10 mg doses are administered as a single spray intranasally into one nostril. Administration of 15 mg and 20 mg doses requires two nasal spray devices, one spray into each nostril. (2.2)
Second Dose: A second dose, when required, may be administered at least 4 hours after the initial dose. If administered, use a new blister pack. (2.2)
Maximum Dosage and Treatment Frequency: Do not use more than 2 doses to treat a single episode. It is recommended that VALTOCO be used to treat no more than one episode every five days and no more than five episodes per month. (2.2)

2.1	Instructions Prior to Dosing

Prior to treatment, healthcare professionals should instruct the individual administering VALTOCO on how to identify seizure clusters and use the product appropriately [see Dosage and Administration (2.3) and Patient Counseling Information (17)].

2.2	Dosing Information

The recommended dose of VALTOCO nasal spray is 0.2 mg/kg to 0.5 mg/kg, depending on the patient's age and weight. See Table 1 and Table 2 for specific recommendations.

Second Dose (if needed): A second dose, when required, may be administered after at least 4 hours after the initial dose. If the second dose is to be administered, use a new blister pack of VALTOCO.

Maximum Dosage and Treatment Frequency: Do not use more than 2 doses of VALTOCO to treat a single episode.

Do not use VALTOCO to treat more than one episode every five days or more than five episodes per month.

2.3	Important Administration Instructions

VALTOCO is for intranasal use only.

No device assembly is required. VALTOCO nasal spray delivers its entire contents upon activation. Do not prime or attempt to use for more than one administration per device.

Patients and caregivers should be counseled to read carefully the "Instructions for Use" for complete directions on how to properly administer VALTOCO.

---

### Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocket [^117MJpQ3]. Nature Communications (2018). Medium credibility.

M. oppositifolius component IVA potently activates KCNQ2

In addition to MTX, previous gas chromatography-mass spectrometry (GCMS) analysis of M. oppositifolius extract identified nine additional compounds, three of which we found to activate KCNQ2/3 channels in our initial screen (Fig. 1). One, IVA, is a phytocompound found both in M. oppositifolius leaf extract and in the extract of valerian root (from Valeriana officinalis) (Fig. 5a). Valerian root has been used in herbal medicine for more than two millennia, in ancient Greece and Rome for disorders including insomnia, and since the sixteenth century in northern England and Scotland for convulsions. As recently as 2002, an estimated 1.1% of the United States adult population (~2 million people) had used valerian root extract in the past week. IVA shares a chemical feature of RTG important for KCNQ2/3 activation, i.e. strongly negative electrostatic surface potential close to a carbonyl oxygen (Fig. 5a) and is predicted by SwissDock to bind close to KCNQ3-W265 (Fig. 5b). In addition to KCNQ2/3 (Fig. 1), IVA potently and effectively activated homomeric KCNQ2 at −60 mV (EC₅₀, 0.34 µM) and, to a lesser extent, KCNQ3* (EC₅₀, 0.5 µM) and KCNQ4 (EC₅₀, 16.2 µM), with no effect on KCNQ5 (Fig. 5c, d; Supplementary Figures 14–17; Supplementary Tables 22–25). Like MTX, IVA did not alter currents generated by KCNA1 (Supplementary Figure 18; Supplementary Table 26).

---

### Diazepam (Valium) [^1144t2TY]. FDA (2025). Medium credibility.

Risks from Concomitant Use with Opioids

Concomitant use of benzodiazepines, including Valium, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe Valium concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of Valium than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking Valium, prescribe a lower initial dose of the opioid and titrate based upon clinical response.

Advise both patients and caregivers about the risks of respiratory depression and sedation when Valium is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see PRECAUTIONS: Drug Interactions).

Abuse, Misuse, and Addiction

The use of benzodiazepines, including Valium, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death (see DRUG ABUSE AND DEPENDENCE: Abuse).

Before prescribing Valium and throughout treatment, assess each patient's risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of Valium, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of Valium along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.

---

### Guidelines for monitoring and management of pediatric patients before, during, and after sedation for diagnostic and therapeutic procedures [^116cwKTV]. Pediatrics (2019). High credibility.

Pediatric sedation drug interaction assessment — herbal and prescription agents can alter sedative effects, so a careful drug history and consultation of interaction resources are advised. An important concern is the widespread use of medications that may interfere with drug absorption or metabolism and therefore enhance or shorten the effect time of sedating medications; herbal medicines (eg, St John's wort, ginkgo, ginger, ginseng, garlic) may alter drug pharmacokinetics through inhibition of the cytochrome P450 system, resulting in prolonged drug effect and altered blood drug concentrations (midazolam, cyclosporine, tacrolimus); kava may increase the effects of sedatives and valerian may itself produce sedation via g-aminobutyric acid mechanisms; drugs such as erythromycin and cimetidine may inhibit the cytochrome P450 system, resulting in prolonged sedation with midazolam; medications used to treat HIV infection, some anticonvulsants, immunosuppressive drugs, and some psychotropic medications may also produce clinically important drug-drug interactions; therefore, a careful drug history is a vital part of the safe sedation of children, and the practitioner should consult various sources for specific information on drug interactions.

---

### Saffron, passionflower, valerian and sage for mental health [^115D1hbr]. The Psychiatric Clinics of North America (2013). Low credibility.

Many cultures have developed folk herbal remedies to treat symptoms of mental illness. An evidence-based view is now being developed for some of these so-called alternative herbal treatments. This article discusses clinically relevant scientific information on medicinal extracts of 4 herbs: saffron, passionflower, valerian, and sage.

---

### Effect of valerian on cognitive disorders and electroencephalography in hemodialysis patients: a randomized, cross over, double-blind clinical trial [^114Ftddd]. BMC Nephrology (2018). Low credibility.

Result

The mean ± SD of patients age was 66.4 ± 14 years in group A and 65.6 ± 12.4 years in group B; the difference was not significant (P = 0.857). Minimum and maximum ages were respectively 35 and 88 years in group A and 41 and 86 years in group B. Females consisted of 52.6% of patients in group A and 45.0% of patients in group B; the difference was not significant (P = 0.634). The mean BMI was 23.6 ± 3.3 kg/m² in group A and 23 ± 3.1 kg/m² in group B; the difference was not significant (P = 0.549). None of the patients in both groups was obese (BMI ≥ 30). All patients in both groups were married, 31.6% in group A and 35% of patients in group B were illiterate. Distribution of patients' literacy level was not significantly different between the two groups (P = 0.588). The level of income was low in 21.1% of patients in group A and 30.0% of patients in group B. Distribution of income between the two groups were not significantly different (P = 0.513). None of the patients in group A was smoker and only 1 patient (5%) in group B was smoking; the difference was not significant (P = 1.00). Diabetes mellitus was the most common cause of dialysis in both groups; the difference was not significant (P = 0.618). In this respect, 26.3% of the patients in group A and 25% of them in group B had heart disease and the difference was not significant (p = 0.925). Moreover, 68.4% of the individuals in group A and 45.0% of them in group B suffered from restless leg syndrome (RLS) although the difference was not significant (p = 0.140). In terms of taking tea, distribution of cups consumed was not significantly different between the two groups (P = 0.857) (Table 1). As well, 68.4% of the patients in group A and 75% of them in group B had a history of hemodialysis of less than 5 years. The mean ± SD of the duration of dialysis in group A patients was also equal to 3.42 ± 2.75 years and they were 3.55 ± 2.96 years in group B patients. The duration of hemodialysis in both groups was not significant (p = 0.945). Duration of hemodialysis in each dialysis session was 4 h in all patients in both groups. In this regard, 26.3% of the patients in group A and 30.0% of them in group B had vascular fistula although the difference was not significant (p = 0.998). Other patients in both groups were also undergoing hemodialysis with long-term hemodialysis catheter (permcath). None of the patients in group A had a history of lung disease and 10% (n = 2) of patients in group B had a history of lung disease; the difference was not significant (P = 0.487). None of the patients had a history of gastrointestinal disease groups. Moreover, 52.6% (n = 10) of patients in group A and 35% (n = 7) of patients in group B were taking hypnotic drugs; the difference was not significant (P = 0.267). Anti-anxiety and anti-depression drugs were not reported in any of the patients in both groups.

---

### Estradiol valerate (Delestrogen) [^11446ZLq]. FDA (2024). Medium credibility.

The dosage of estradiol valerate IM for treatment of prostate cancer adults (advanced) is 30 mg IM q1-2 weeks

---

### Valacyclovir hydrochloride (Valtrex) [^113VRK8w]. FDA (2022). Medium credibility.

Regarding the use of valacyclovir hydrochloride PO (also known as Valtrex) in patients with continuous renal replacement:

- Reduce dose.
- Dose as in eGFR 10–30 mL/min/1.73 m².

---

### Addressing barriers to reducing prescribing and implementing deprescribing of sedative-hypnotics in primary care [^1119h8PP]. The Annals of Pharmacotherapy (2022). Medium credibility.

Nurses and pharmacists can also provide patient education and empowerment regarding deprescribing. Lopez-Peig et alevaluated a nurse-led benzodiazepine withdrawal program using a before-after study design in 2 primary care centers (n = 51 participants). Nurses provided patient education, and SH doses were reduced every 2 to 4 weeks by approximately 25%. Alternative drugs valerian or hydroxyzine were permitted for sleep to support benzodiazepine tapering. At 6 months, 80% of the patients had discontinued benzodiazepine use and 64% maintained discontinuation at 1 year. Those who successfully discontinued benzodiazepine therapy reported improvements in depression and anxiety without reduction in sleep quality. A pharmacy-based patient education program was examined in 2 randomized controlled trials. Tannenbaum et alconducted a cluster randomized trial to compare the effect of a direct-to-consumer education tool versus usual care via 30 community pharmacies in Québec. Pharmacies were randomly allocated to the intervention, which involved mailing an 8-page brochure to chronic benzodiazepine users aged 65 years and older either immediately (intervention) or after a 6-month wait period (control). The brochure included education about harms, peer support stories, a tapering protocol, and alternatives. At 6 months, 27% of the intervention group had discontinued therapy versus 5% of the control group (risk difference = 23%; 95% CI = 14%-32%), and 11% had reduced their dose (95% CI = 6%-16%). Lack of physician support was identified as a deterrent to deprescribing. To address this barrier, a second randomized trial that added an evidence-based pharmaceutical opinion sent to physicians, at the same time as pharmacists mailed the education brochure to patients, sought to better foster communication around deprescribing. The study enrolled 489 participants from 69 community pharmacies who were prescribed 1 of 4 Beers Criteria medications (SH, nonsteroidal anti-inflammatories, glyburide, or first-generation antihistamine). SH discontinuation was 43.2% for the intervention group versus 9.0% for the control group (risk difference = 34%; 95% CI = 25%-43%); 38% of individuals who attempted to taper SH reported withdrawal symptoms.

---

### Diazepam (Valtoco) [^113xpWZr]. FDA (2025). Medium credibility.

5.1	Risk of Concomitant Use with Opioids

Concomitant use of benzodiazepines, including VALTOCO, and opioids may result in profound sedation, respiratory depression, coma, and death [see Drug Interactions (7.1)]. Because of these risks, reserve concomitant prescribing of benzodiazepines and opioids for patients for whom alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe VALTOCO concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. Advise both patients and caregivers about the risks of respiratory depression and sedation when VALTOCO is used with opioids.

5.2	Abuse, Misuse, and Addiction

The use of benzodiazepines, including VALTOCO, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death [see Drug Abuse and Dependence (9.2)].

Before prescribing VALTOCO and throughout treatment, assess each patient's risk for abuse, misuse, and addiction. Use of VALTOCO, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of VALTOCO along with monitoring for signs and symptoms of abuse, misuse, and addiction. Do not exceed the recommended dosing frequency; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.

---

### The chronic effects of a combination of herbal extracts (euphytose) on psychological mood state and response to a laboratory stressor: a randomised, placebo-controlled, double blind study in healthy humans [^112BwuYB]. Journal of Psychopharmacology (2022). Medium credibility.

Methods

Study design

A randomised, placebo-controlled, double-blind, crossover design was utilised. Participants attended the Brain, Performance and Nutrition Research Centre laboratory at Northumbria University and were assessed after 14 days supplementation with MHEP and a matched placebo. The study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki (1996). The trial was conducted in compliance with protocol/GCP/applicable regulatory requirements and commenced only when a favourable ethical opinion was obtained from the University of Northumbria Department of Psychology Ethics Committee, United Kingdom, approval number 13339.

Determination of sample size

The power calculation was made with reference to the medium effect size (Cohen's d = 0.56) reported in the study byfor the effect of a combination product containing valerian, passion flower and lemon balm on anxiety as measured using the STAI-State subscale, administered before and at several time points after a psychological stressor. Therefore, with a mixed design study involving the within-subjects factors of treatment and assessment and the between-subjects factor of treatment order on the primary outcome measure (state anxiety-STAI), a total sample size of 28 participants was required to meet the conventionally accepted 80% power to detect a significant difference (α = 0.05) between treatments.

---

### Valsartan oral (valsartan) [^116Xp3Q5]. FDA (2025). Medium credibility.

14.2 Heart Failure

The valsartan Heart Failure Trial (Val-HeFT) was a multinational, double-blind study in which 5,010 patients with NYHA class II (62%) to IV (2%) heart failure and LVEF < 40%, on baseline therapy chosen by their physicians, were randomized to placebo or valsartan (titrated from 40 mg twice daily to the highest tolerated dose or 160 mg twice daily) and followed for a mean of about 2 years. The VAL-HeFT study was conducted with a formulation of valsartan that is not therapeutically equivalent to valsartan oral solution [see Clinical Pharmacology (12.3)]. Although Val-HeFT's primary goal was to examine the effect of valsartan when added to an ACE inhibitor, about 7% were not receiving an ACE inhibitor. Other background therapy included diuretics (86%), digoxin (67%), and beta-blockers (36%). The population studied was 80% male, 46% 65 years or older and 89% Caucasian. At the end of the trial, patients in the valsartan group had a blood pressure that was 4 mmHg systolic and 2 mmHg diastolic lower than the placebo group. There were two primary end points, both assessed as time to first event: all-cause mortality and heart failure morbidity, the latter defined as all-cause mortality, sudden death with resuscitation, hospitalization for heart failure, and the need for intravenous inotropic or vasodilatory drugs for at least 4 hours. These results are summarized in the following table.

Although the overall morbidity result favored valsartan, this result was largely driven by the 7% of patients not receiving an ACE inhibitor, as shown in the following table.

The modest favorable trend in the group receiving an ACE inhibitor was largely driven by the patients receiving less than the recommended dose of ACE inhibitor. Thus, there is little evidence of further clinical benefit when valsartan is added to an adequate dose of ACE inhibitor.

Secondary end points in the subgroup not receiving ACE inhibitors were as follows.

In patients not receiving an ACE inhibitor, valsartan-treated patients had an increase in ejection fraction and reduction in left ventricular internal diastolic diameter (LVIDD).

Effects were generally consistent across subgroups defined by age and gender for the population of patients not receiving an ACE inhibitor. The number of black patients was small and does not permit a meaningful assessment in this subset of patients.

---

### Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine-recommendations of the advisory committee on immunization practices (ACIP) [^114fdFKL]. MMWR: Recommendations and Reports (2010). Medium credibility.

ACIP table 11 — PCV13 catch-up schedule for children aged ≥ 24 months by prior pneumococcal conjugate vaccine (PCV) history: For 24–59 mos in healthy children, unvaccinated or any incomplete schedule receives 1 dose, and those with 4 doses of PCV7 or other age-appropriate, complete PCV7 schedule receive 1 supplemental dose, ≥ 8 weeks after the most recent dose. For 24–71 mos in children with underlying medical conditions, unvaccinated or any incomplete schedule of < 3 doses receives 2 doses, the first dose ≥ 8 weeks after the most recent dose and a second dose ≥ 8 weeks later; any incomplete schedule of 3 doses receives 1 dose, ≥ 8 weeks after the most recent dose; and 4 doses of PCV7 or other age-appropriate complete PCV7 schedule receives 1 supplemental dose, ≥ 8 weeks after the most recent dose. Minimum interval between doses is 8 weeks.

---

### Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine-recommendations of the advisory committee on immunization practices (ACIP) [^114u51Zb]. MMWR: Recommendations and Reports (2010). Medium credibility.

PCV13 catch-up for children aged 12–23 mos — With 0 prior doses give 2 doses, ≥ 8 weeks apart; with 1 dose before age 12 mos give 2 doses, ≥ 8 weeks apart; with 1 dose at ≥ 12 mos give 1 dose, ≥ 8 weeks after the most recent dose; with 2 or 3 doses before age 12 mos give 1 dose, ≥ 8 weeks after the most recent dose; if 4 doses of PCV7 or another age-appropriate, complete PCV7 schedule were received, give 1 supplemental dose ≥ 8 weeks after the most recent dose; no additional PCV13 doses are indicated for children aged 12–23 months who previously received 2 or 3 PCV7 doses before age 12 months and at least 1 PCV13 dose at age ≥ 12 months.

---

### Valacyclovir hydrochloride (Valtrex) [^113nXY8L]. FDA (2022). Medium credibility.

The dosage of valacyclovir hydrochloride PO for treatment of varicella zoster virus infection in adults with human immunodeficiency virus infection is 1 g PO TID for at least 5 to 7 days and until all lesions have crusted

---

### The peri-operative implications of herbal medicines [^117T23yz]. Anaesthesia (2002). Low credibility.

An increasing number of patients are taking herbal medicines such as echinacea, garlic, ginkgo biloba, ginseng, St John's Wort, valerian, ephedra, kava, grapefruit juice and ginger. Although these herbal medications are considered 'natural' products that may have some benefits, adverse effects such as increased bleeding tendencies and drug interactions are associated with their use. Surgeons and anaesthetists may be unaware of their patients' use of these medications because it is common for patients not to disclose their use of this form of medication, and both surgeons and anaesthetists often fail to enquire about their use. Anaesthetists and surgeons must be familiar with the effects of herbal medicines and should specifically enquire about the use of herbal medicines during pre-operative assessment. Currently available data suggest that all herbal medicines should be ceased 2 weeks before surgery.

---

### Methodology for ACOEM's occupational medicine practice guidelines-2025 revision [^114ZebCv]. ACOEM (2025). High credibility.

ACOEM Occupational Medicine Practice Guidelines methodology — recommendation format and content: All recommendations are clearly stated and are in bold type, with indications provided to clarify circumstances for consideration; documentation records the dose/frequency, discontinuation as appropriate, and harms/benefits, and when the highest quality study specifies dose or frequency, that information is preferentially referenced in the recommendation's dose/frequency section; strong recommendations are stated as "Strongly Recommended, Evidence A" in bold; each recommendation has an evidence table indicating the high and moderate quality studies, and specific reference citations in the rationale provide an explicit link between recommendations and evidence; guidance further states "Recommendations should be articulated in a standardized form detailing precisely what the recommended action is and under what circumstances it should be performed", and "Strong recommendations should be worded so that compliance with the recommendation(s) can be evaluated".

---

### Diazepam (Valium) [^1159vCaY]. FDA (2025). Medium credibility.

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS).
The use of benzodiazepines, including VALIUM, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALIUM and throughout treatment, assess each patient's risk for abuse, misuse, and addiction (see WARNINGS).
The continued use of benzodiazepines, including VALIUM, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of VALIUM after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALIUM or reduce the dosage (see DOSAGE AND ADMINISTRATION and WARNINGS).

---

### Herbal medicines and perioperative care [^112wD1Lo]. JAMA (2001). Excellent credibility.

Context

Widespread use of herbal medications among the presurgical population may have a negative impact on perioperative patient care.

Objectives

To review the literature on commonly used herbal medications in the context of the perioperative period and provide rational strategies for managing their preoperative use.

Data Sources

The MEDLINE and Cochrane Collaboration databases were searched for articles published between January 1966 and December 2000 using the search terms herbal medicine, phytotherapy, and alternative medicine and the names of the 16 most commonly used herbal medications. Additional data sources were obtained from manual searches of recent journal articles and textbooks.

Study Selection

We selected studies, case reports, and reviews addressing the safety and pharmacology of 8 commonly used herbal medications for which safety information pertinent to the perioperative period was available.

Data Extraction

We extracted safety, pharmacodynamic, and pharmacokinetic information from the selected literature and reached consensus about any discrepancies.

Data Synthesis

Echinacea, ephedra, garlic, ginkgo, ginseng, kava, St John's wort, and valerian are commonly used herbal medications that may pose a concern during the perioperative period. Complications can arise from these herbs' direct and pharmacodynamic or pharmacokinetic effects. Direct effects include bleeding from garlic, ginkgo, and ginseng; cardiovascular instability from ephedra; and hypoglycemia from ginseng. Pharmacodynamic herb-drug interactions include potentiation of the sedative effect of anesthetics by kava and valerian. Pharmacokinetic herb-drug interactions include increased metabolism of many drugs used in the perioperative period by St John's wort.

Conclusions

During the preoperative evaluation, physicians should explicitly elicit and document a history of herbal medication use. Physicians should be familiar with the potential perioperative effects of the commonly used herbal medications to prevent, recognize, and treat potentially serious problems associated with their use and discontinuation.

---

### NCCN guidelines® insights: bladder cancer, version 3.2024 [^116cK9FA]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

Regarding therapeutic procedures for bladder cancer - NCCN, more specifically with respect to intravesical therapy, NCCN 2024 guidelines recommend to follow the intravesical BCG principles during time of BCG shortage:

- prioritze BCG induction and maintenance for patients at high risk for recurrence (such as high-grade T1 and CIS), especially in the early maintenance period (3 and 6 months post-induction)

- consider risk adapting BCG maintenance for patients with intermediate-risk non-muscle-invasive bladder cancer to prioritize patients with high-risk non-muscle-invasive bladder cancer

- stop BCG maintenance for patients with high-risk non-muscle-invasive bladder cancer at 1 year

- consider offering induction with alternative agents if BCG is completely not available; Alternative options include: sequential gemcitabine/docetaxel, mitomycin, gemcitabine, epirubicin, valrubicin, docetaxel, or sequential gemcitabine/mitomycin

- consider offering a clinical trial if available

- consider splitting the dose of BCG (1/3 or 1/2 dose), if feasible, so that multiple patients may be treated with a single vial (for induction or high-priority maintenance therapy).

---

### Effect of valdecoxib pretreatment on pain and secondary hyperalgesia: a randomized controlled trial in healthy volunteers [ISRCTN05282752, NCT00260325] [^112wJBEg]. BMC Anesthesiology (2006). Low credibility.

Conclusion

We demonstrated in a double-blind, cross-over, prospective study that a single, orally administered dose of valdecoxib does not attenuate secondary hyperalgesia/allodynia induced by the skin heat/capsaicin sensitization model, when compared to placebo.

---

### Optimal preoperative assessment of the geriatric surgical patient: a best practices guideline from the American college of surgeons national surgical quality improvement program and the American Geriatrics Society [^112NwyMv]. Journal of the American College of Surgeons (2012). Medium credibility.

Appendix VI — preoperative discontinuation of herbal medicines/supplements — details perioperative concerns and timing for stopping common agents as follows: Ephedra poses "risk of myocardial ischemia and stroke… " and "life-threatening interaction with monoamine oxidase inhibitors"; discontinue "At least 24 hours before a surgical operation". Garlic has "Potential to increase risk of bleeding, especially when combined with other medications that inhibit platelet aggregation"; discontinue "At least 7 days before a surgical operation". Ginkgo has "Potential to increase risk of bleeding, especially when combined with other medications that inhibit platelet aggregation"; discontinue "At least 36 hours before a surgical operation". Ginseng lists "Hypoglycemia; potential to increase risk of bleeding; potential to decrease anticoagulation effect of warfarin"; discontinue "At least 7 days before a surgical operation". Kava has "Potential to increase sedative effect of anesthetics; potential for addiction, tolerance, and withdrawal after abstinence unstudied"; discontinue "At least 24 hours before a surgical operation". St. John's wort causes "Induction of cytochrome P450 enzymes…; decreased serum digoxin levels"; discontinue "At least 5 days before a surgical operation". Echinacea notes "Allergic reaction; decreased effectiveness of immunosuppressants; potential for immunosuppression with long-term use" with "No data" for discontinuation timing. Valerian notes "Potential to increase sedative effect of anesthetics; benzodiazepine-like acute withdrawal; potential to increase anesthetic requirements with long-term use" with "No data" for discontinuation timing.

---

### Valacyclovir hydrochloride (Valtrex) [^112C4Kb8]. FDA (2022). Medium credibility.

Regarding the use of valacyclovir hydrochloride PO (also known as Valtrex) in patients with chronic liver disease, any severity:

- Use acceptable.
- No dose adjustment required.

---

### Diazepam [^114P2qNp]. FDA (2024). Medium credibility.

Regarding the use of diazepam IV (also known as Valium, Valtoco, Diastat) in patients with chronic liver disease, any severity:

- No dose adjustment required. Use with caution.

---

### Acute liver injury after long-term herbal "Liver cleansing" and "Sleep aid" supplement use [^116SofdR]. The Journal of Emergency Medicine (2021). Medium credibility.

Background

Acute liver injury is reported in association with toxins, pharmaceuticals, and viral infections. Increasingly prevalent are cases of herbal- and dietary supplement-related hepatotoxicity. Early recognition of this potentially life-threatening complication by emergency care providers leads to more appropriate management and disposition.

Case Report

A 53-year-old woman presented to the emergency department with a 3-day history of jaundice and increased abdominal girth after a month-long use of a combination herbal "liver-cleansing" compound and a nightly herbal "sleep aid". The "Liver Detoxifier and Regenerator" listed multiple constituents, including concentrated scute root and turmeric root; "Restful Sleep" listed multiple constituents, including valerian. Emergency department evaluation revealed marked hyperbilirubinemia with liver enzyme elevations indicative of cholestatic jaundice. Imaging studies, including ultrasound and abdominal magnetic resonance imaging, revealed hepatomegaly and steatosis without biliary dilatation; a biopsy specimen was obtained, and the results were consistent with drug-induced liver injury. The patient's liver function abnormalities gradually improved with discontinuation of the products as well as a tapered course of corticosteroid therapy. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS? A significant proportion of the U.S. adult population uses herbal and dietary supplements. Most patients do not discuss nonprescription medication use with their providers and many physicians will not specifically ask about herbal supplements. It is important for emergency physicians to be aware of the potential for herbal supplements to contribute to acute liver injury and be able to investigate the active agents reported in these formulations. The diagnostic criteria for cholestatic jaundice and drug-induced liver injury are discussed.

---

### Herbs commonly used by women: an evidence-based review [^112M8d4s]. American Journal of Obstetrics and Gynecology (2003). Low credibility.

Objective

To review the evidence of herbs commonly used by women.

Data Sources

Articles were located by searching Medline, Cochrane Database of Systemic Reviews, and the Combined Health Information Database and by hand searching the reference lists of recent systematic reviews. The databases were searched in January 2000 and October 2000 by using the Latin and common name of each herb.

Methods Of Study Selection

Preference was given to randomized, placebo-controlled trials. When available, English language studies were reviewed. If not, data are presented from review articles that summarize the foreign study.

Results

Many women use herbal therapies. In the United States, herbs are considered dietary supplements. The Food and Drug Administration (FDA) cannot remove them from the market unless they are proven unsafe. The herb industry plans to improve monitoring. Many prospective randomized controlled trials are being funded. Gingko biloba seems to slow the progression of dementia but increases the risk of bleeding. St John's Wort is efficacious for treating mild to moderate depression but has many drug interactions. Ginseng seems to improve well being in perimenopausal women, but it is often impure and has side effects and drug interactions. Garlic slightly lowers blood pressure and lipids. Echinacea slightly decreases the duration of colds but does not prevent them. Valerian is beneficial for insomnia, but there is no long-term safety data. Black cohosh may help the symptoms of perimenopause, and chasteberry may improve premenstrual syndrome. More study is needed on both herbs.

Conclusion

Some herbs are medically useful, but the American public would benefit from increased regulation. Manufacturers should be able to ensure that herbs contain pure ingredients. Side effects and drug interactions should be listed. Well-designed studies are being conducted. The results will be helpful to physicians and patients when the clinical evidence becomes available.

---

### Nutritional and herbal supplements in the treatment of obsessive compulsive disorder [^112jKWDz]. General Psychiatry (2020). Medium credibility.

Milk thistle (Silybum marianum)

Silybum marianum (milk thistle) is a medicinal plant, which is grown in Mediterranean and Persian regions. It contains flavonoid complex silymarin, which has anti-inflammatory, antioxidant, immune modulator, sedative and antidepressant effects. Also silymarin has been found to increase serotonin in the cortex and acts as a monoamine oxidase inhibitor.

Results of the only randomised controlled trial (n = 35) of milk thistle for OCD treatment revealed no significant difference in treatment effects between milk thistle (600 mg/d) and fluoxetine. It is indicated that milk thistle has similar effects with fluoxetine in OCD symptoms and its positive effect starts in the fifth week without severe side effects.

Valerian root (Valeriana officinalis L)

Valerian is a perennial plant, which was used as a perfume in the 16th century. Valerian roots have aleuronic acid that is associated with the modulation of GABA A receptors. The other content of valerian roots is valepotriates, which is effective in treating the psychotic symptoms of severe anxiety. Valerian is most commonly used in insomnia and migraine treatment due to its sedative, pain reliever effects. There is only one double-blind placebo-controlled trial of valerian extract in OCD treatment (n = 31). They found that valerian extract was more effective in OCD treatment compared with placebo. Also, they observed the rapid onset of the effects of extract (28, 42, 56 days). Low incidence of impairment of libido with valerian extract was an important advantage of this treatment.

---

### Valacyclovir hydrochloride (Valtrex) [^115ykVhK]. FDA (2022). Medium credibility.

The dosage of valacyclovir hydrochloride PO for prevention of varicella zoster virus infection in adults with immunocompromising conditions is 500 mg PO BID for 3 to 6 months

---

### Diazepam (Valtoco) [^114pegmc]. FDA (2025). Medium credibility.

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].
The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each patient's risk for abuse, misuse, and addiction [see Warnings and Precautions (5.2)].
The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although VALTOCO is indicated only for intermittent use [see Indications and Usage (1) and Dosage and Administration (2)], if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening. For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO [see Warnings and Precautions (5.3)].

---

### SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols [^116UBWVs]. EClinicalMedicine (2025). Medium credibility.

The probability of the true DLT rate for each dose level will be summarized as follows:

- [0%, 20%) Under-dosing interval
- [20%, 33%) Targeted toxicity interval
- [33%, 100%] Excessive toxicity interval

The probability of DLT will be calculated by BLRM, as described above, when all subjects in a dose cohort finish the DLT evaluation period. The highest dose level for the next dose cohort will be recommended using the probability of DLTs at all dose levels of study drug. The highest dose will need to satisfy EWOC principle, ie, less than 25% probability that the estimated DLT rate is in the excessive toxicity interval, and also to have the highest probability that the estimated DLT rate is in the target toxicity interval".

This example lacks a more explicit explanation regarding the rationale behind selecting a target risk/toxicity rate.

---

### Paregoric [^111uauQF]. FDA (2018). Low credibility.

DOSAGE AND ADMINISTRATION

Usual Pediatric Dosage

0.25 to 0.5 mL/kg of body weight 1 to 4 times a day or as directed by a physician.

Usual Adult Dosage

5 to 10 mL 1 to 4 times a day or as directed by a physician.

---

### Valacyclovir hydrochloride (Valtrex) [^112bRXAf]. FDA (2022). Medium credibility.

The dosage of valacyclovir hydrochloride PO for adjunctive treatment for acute retinal necrosis in adults with human immunodeficiency virus infection (caused by varicella zoster virus) is 1 g PO TID for at least 14 weeks

---

### Diazepam (Valium) [^1115PZ2g]. FDA (2025). Medium credibility.

Dependence and Withdrawal Reactions

To reduce the risk of withdrawal reactions, use a gradual taper to discontinue Valium or reduce the dosage (a patient-specific plan should be used to taper the dose) (see DOSAGE AND ADMINISTRATION: Discontinuation or Dosage Reduction of Valium).

Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use.

Acute Withdrawal Reactions

The continued use of benzodiazepines, including Valium, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of Valium after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) (see DRUG ABUSE AND DEPENDENCE: Dependence).

Protracted Withdrawal Syndrome

In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months (see DRUG ABUSE AND DEPENDENCE: Dependence).

Valium is not recommended in the treatment of psychotic patients and should not be employed instead of appropriate treatment.

Since Valium has a central nervous system depressant effect, patients should be advised against the simultaneous ingestion of alcohol and other CNS-depressant drugs during Valium therapy.

As with other agents that have anticonvulsant activity, when Valium is used as an adjunct in treating convulsive disorders, the possibility of an increase in the frequency and/or severity of grand mal seizures may require an increase in the dosage of standard anticonvulsant medication. Abrupt withdrawal of Valium in such cases may also be associated with a temporary increase in the frequency and/or severity of seizures.

---

### Valsartan (Diovan) [^1154P6ky]. FDA (2025). Medium credibility.

Common adverse reactions (1–10%) associated with the use of valsartan PO (also known as Diovan, Prexxartan) include: abdominal pain, arthralgia, ataxia, back pain, ↓ blood neutrophil count, blurred vision, change in taste, cough, decreased libido, diarrhea, fatigue, headache, hypotension, nausea, ↑ serum creatinine, ↑ serum potassium, syncope, upper respiratory tract infections and ↓ WBC count.

---

### Popescu technique revisited: review of the literature and case series [^1114JkHm]. Journal of Oral and Maxillofacial Surgery (2020). Medium credibility.

Management of vascular malformations depends on the size, type, age of the patient, location, dissemination, and depth of penetration. Treatment options include propranolol, which reduces endothelial vessel proliferation, minimally invasive sclerotherapy to induce fibrosis, or surgery. In 1985, Valerian Popescu described a new approach to treatment consisting of intratumoral ligation by compartmentalization. This technique allows for high doses of the sclerosant agent to be delivered as systemic dissemination is restricted by a series of strangulating suture loops that divide the mass into segments. We describe the management and outcome of 2 patients who presented with vascular malformations in the orofacial region and were managed using a Popescu suturing technique. Vascular obliteration was achieved by a series of strangulating suture loops placed percutaneously throughout each lesion using a curved needle with a resorbable material (Vicryl; Ethicon, Somerville, NJ). The aim was to segment the vascular malformation into manageable sections for subsequent injection of a sclerosant. The compartmentalization also ensured that the sclerosant stayed within these compartments and was not washed out into the general circulation. Good esthetic outcomes were achieved in very visible areas such as the commissure and the vermillion border. In these areas, a surgical resection would have certainly caused a disruption of the esthetics of the lips and, in the second case, probably an alteration of function. Intratumoral ligation can be used safely to achieve control of vascular malformations with good esthetic outcomes.

---

### Valbenazine (Ingrezza) [^114f5SLr]. FDA (2025). Medium credibility.

12.3 Pharmacokinetics

Valbenazine and its active metabolite ([+]-α-HTBZ) demonstrate approximate proportional increases for the area under the plasma concentration versus time curve (AUC) and maximum plasma concentration (Cmax) after single oral doses from 40 mg to 300 mg (i.e., 50% to 375% of the recommended treatment dose).

Absorption

INGREZZA

Following oral administration of INGREZZA, the time to reach maximum valbenazine plasma concentration (tmax) ranges from 0.5 to 1.0 hours. Valbenazine reaches steady state plasma concentrations within 1 week. The absolute oral bioavailability of valbenazine is approximately 49%.-α-HTBZ gradually forms and reaches Cmax4 to 8 hours after administration of INGREZZA.

INGREZZA SPRINKLE

Following administration of 80 mg INGREZZA SPRINKLE orally as sprinkle on applesauce, the geometric mean peak plasma concentration (Cmax) of valbenazine was 512 ng/mL, area under the plasma concentration-time curve (AUCinf) was 5,600 ng*hr/mL and the median time to reach Cmax(Tmax) was 1.5 hours. For the-α-HTBZ metabolite, the geometric mean Cmaxwas 23 ng/mL, AUCinfwas 739 ng*hr/mL and the median Tmaxwas 6 hours.

---

### Management of premenstrual disorders: ACOG clinical practice guideline no. 7 [^115PxcVv]. Obstetrics and Gynecology (2023). High credibility.

Vitex agnus castus — Evidence from low- to moderate-quality randomized controlled trials demonstrates that Vitex agnus castus is well tolerated and associated with an improvement in premenstrual symptoms, but interpretation is limited by high heterogeneity of formulations and dosages. Given this uncertainty, ACOG agrees that further study is needed before a recommendation can be made about its use for premenstrual symptoms.

---

### Allergen immunotherapy: a practice parameter third update [^115ndD6L]. The Journal of Allergy and Clinical Immunology (2011). Medium credibility.

Allergen immunotherapy — dose selection and maintenance concentrate: The efficacy of immunotherapy depends on achieving an optimal therapeutic dose of each of the constituents in the allergen immunotherapy extract, and the maintenance dose of allergen immunotherapy must be adequate; low maintenance doses are generally not effective (eg, dilutions of 1:1,000,000, 1:100,000, and 1:10,000 vol/ vol). A consideration when mixing extracts is the need to deliver an optimal therapeutically effective dose of each constituent because dilution when one mixes multiple extracts will decrease the concentration of each in the final mixture and reduce efficacy. The maintenance concentrate should be formulated to deliver a dose considered to be therapeutically effective for each of its constituent components, and the maintenance concentrate vial is the highest concentration allergen immunotherapy vial (eg, 1:1 vol/ vol). The projected effective dose is called the maintenance goal, but some subjects unable to tolerate the projected effective dose will experience clinical benefits at a lower dose, and the maintenance dose is the dose that provides therapeutic efficacy without significant adverse local or systemic reactions and might not always reach the initially calculated projected effective dose; this reinforces that allergen immunotherapy must be individualized. Some patients might not tolerate the targeted therapeutic dose and their maintenance dose would be lower (eg, 500 BAU vs 2000 BAU for cat), and subjects who have systemic reactions with doses that are less than the projected effective dose should be maintained on the highest tolerated dose, providing this dose is effective.

---

### Change in use of sleep medications after gastric bypass surgery or intensive lifestyle treatment in adults with obesity [^111MKK6p]. Obesity (2017). Low credibility.

Outcome and follow‐up

The main outcome was hypnotics and/or sedatives prescriptions filling, identified via the nationwide Prescribed Drug Register through the World Health Organization Anatomical Therapeutic Chemical (ATC) codes under N05C (Supporting Information Table S2). Medications were excluded if their primary indication included health conditions other than sleep problems, such as mental health disorders (clomethiazole [N05CM02] and Valerianae radix [N05CM09]). Midazolam (N05CD08) was excluded as it is indicated for preoperative sedation. Collectively, the excluded medications constituted 0.26% of all sleep medication prescriptions in the matched data set throughout the entire study period.

The categorical outcome was defined as the proportion of individuals with at least one filled prescription of the selected medications in a given year. The continuous outcome was defined as annual mean treatment dose of hypnotics and/or sedatives, calculated as follows:where defined daily doses (DDDs) refers to the daily dose of a particular medication recommended by the World Health Organization 21.

Individuals were followed from treatment initiation until death or end of follow‐up, whichever came first. All individuals in the current data set had at least 3 years follow‐up. We also created a second matched data set composed of the subgroup of individuals with 5 years follow‐up.

Covariates

Baseline weight and height measurements were used to calculate BMI. Poor mental health was defined as a history of inpatient stays or outpatient visits for psychiatric disorders (ICD10: F00‐F99) and/or prescribed medications for mental health disorders (ATC codes: N06, N05A, and N05B). In the surgery cohort, information on use of continuous positive airway pressure (CPAP) was obtained during clinical examination at baseline. History of inpatient stays and outpatient visits for any cause were identified through the National Patient Register, and prescription history was identified from the Prescribed Drug Register.

---

### Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study [^111bkH3S]. Clinical Pharmacology and Therapeutics (2021). Medium credibility.

Exposure assessment

Exposure of interest was administration of any of the potential moderate/strong DOAC‐interacting drugs. These included potential P‐gp/CYP3A4 inhibitors,: amiodarone, dronedarone, verapamil, diltiazem, clarithromycin, ketoconazole, fluconazole, itraconazole, voriconazole, ritonavir, erythromycin; bisoprolol (a potential CYP3A4 inhibitor); and amlodipine (a P‐gp inhibitor, without CYP3A4 inhibition effect). Second, we evaluated exposure to potential P‐gp/CYP3A4 inducers,: rifampicin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, Hyperici herba, and topiramate. We also evaluated the effect of exposure to valproic acid or levetiracetam on treatment efficacy, due to the controversial data regarding the effect of these medications on CYP3A4 activity and P‐gp induction, and the potential interest in these medications as safer alternatives to enzyme inducing medications in patients treated with DOACs who require anti‐seizure medications.

For cases and controls, exposure was defined as dispensing an interacting drug up to 3 months before the index date. For active comparison (i.e. negative control object), we chose drugs used for similar purposes that had not been previously associated with P‐gp/CYP3A4 inhibition or induction: beta‐adrenergic receptor blockers, propafenone, azithromycin, and tetracycline antibiotics as comparators of P‐gp/CYP3A4 inhibitors; lamotrigine, clonazepam, gabapentin, and valerianae radix as comparators for the P‐gp/CYP3A4 inducers.

---

### Valrubicin (Valstar) [^113DQLM6]. FDA (2024). Medium credibility.

Unknown frequency adverse reactions associated with the use of valrubicin intravesical (also known as Valstar) include: ↓ blood neutrophil count and ↓ WBC count.

---

### Valsartan (Diovan) [^111TsEH3]. FDA (2025). Medium credibility.

Unknown frequency adverse reactions associated with the use of valsartan PO (also known as Diovan, Prexxartan) include: anaphylaxis, angioedema, chest pain, hair loss, hepatitis, ↑ liver enzymes, loss of appetite, orthostatic hypotension, ↓ platelet count, renal failure, rhabdomyolysis, tachycardia, vasculitis and vomiting.